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ABSTRACT 
Breast cancer is the second leading cause of cancer related death in women worldwide1. 
Although majority of primary breast cancers are curable with current treatment strategies, 
treatment outcome of metastatic breast cancer is dismal. The main focus of my doctoral studies 
is to investigate the causes of breast cancer recurrences and to eventually improve the survival 
outcome of metastatic breast cancer. Several factors has been attributed for the recurrence of 
breast cancer such as presence of cancer stem cells (CSCs) and the ongoing genomic evolution 
of cancer cells leading to intra tumor heterogeneity, which can in turn give rise to therapy 
resistant subclones. In this thesis we sought to investigate these two factors using breast cancer 
specimens. 
Firstly, in paper I, we optimized the method called “superficial scraping from tumor”. Using 
this method we were able to isolate epithelial breast cancer cells from which we can generate 
CSCs with ultra-low attachment and serum free conditions. Mammospheres generated from 
scraping material phenotypically resemble CSCs with ALDH1+, CD44+, and CD24- 
expression. Apart from CSC generation, scraping method can be used to biobank small tumors 
for future research purposes, without compromising routine histopathological analysis of 
patient samples. Next, we evaluated the expression of second estrogen receptor ERβ and its 
role in patient derived CSCs (Paper II), using the method optimized from paper I. We found 
that ERβ was predominantly expressed in both normal mammary stem cells (MSC) and CSCs. 
ERβ was found to be crucial for cancer stem cell phenotype and stimulation of ERβ using 
specific agonist increased mammosphere formation. Microarray analysis on ERβ stimulated 
MCF7 derived mammospheres, identified enhanced glycolysis metabolism pathway. 
Antagonizing ERβ in cell lines and in patient derived xenografts (PDX) demonstrated that ERβ 
is a therapeutical target in breast cancer and can be utilized to specifically target the CSC 
population.  
Tamoxifen is an important therapy for ERα positive breast cancers, however around 30-40% 
of patients relapse during endocrine therapy2. To investigate the endocrine resistance from a 
cancer stem cell perspective (Paper III), we treated adherent breast cancer cells (ER+) and 
CSCs with tamoxifen. Interestingly, CSCs where found to be resistant to tamoxifen treatment, 
while tamoxifen inhibited the adherent cancer cell population. To understand the mechanism 
behind the CSC induced endocrine resistance, we performed microarray analysis on patient 
derived CSCs treated with tamoxifen. Interestingly, mTOR signaling related pathways were 
found to be induced by tamoxifen in CSCs. This induction of mTOR effector downstream 
targets were observed only in CSCs but not in adherent cancer cells. Further, mTOR signaling 
was also found to be elevated in CSCs compared to the adherent cancer cell population. mTOR 
inhibitors such as rapamycin and everolimus were found to be effective in reducing the 
mammosphere formation. Therefore, combined tamoxifen and mTOR inhibitors can 
effectively target both differentiated cancer cells and the CSC population.  
Next, we explored the genomic landscape of metastases, patterns of metastatic spread and the 
role of axillary lymph node metastasis in seeding distant metastasis (Paper IV). We performed 
whole exome sequencing on 99 tumor samples from 20 breast cancer patients with matched 
primary and metastatic lesions. We observed both linear progression (i.e. metastasis seeding 
successive distant metastasis) and parallel progression (i.e. different distant metastasis were 
seeded from primary tumor directly rather than seeded by other distant metastasis) model 
during breast cancer progression. Majority of the distant metastasis where polyclonally seeded. 
We observed lack of axillary lymph node involvement in seeding distant metastasis. This 
indicates that, the majority of cancer cells are seeded hematogenously rather than utilizing the 
lymphatic system for cancer spreading. On average, only half of primary mutations were 
retained in the distant metastatic lesions with considerable disparity between individual patients 
ranging from 9 to 88%.  Several putative driver alterations occurred late, privately in distant 
metastasis, highlighting the need to characterize the genomic alterations of metastatic lesions 
for making better informed clinical decision at metastatic setting. Further, we also observed 
specific mutational signatures such as APOBEC-associated signature, were significantly higher 
in distant metastasis compared to their respective primary tumors. Finally, in paper V, we 
profiled (RNA sequencing) multiple regions of the same tumor from 12 breast cancers. 
Molecular subtypes and transcriptomic grades for each tumor piece was determined. Primary 
breast cancers exhibited substantial intra-tumor genomic heterogeneity, but limited 
transcriptomic heterogeneity at macroscopic level. Our data suggested that, intra-tumoural 
heterogeneity is unlikely to have an impact on transcription based molecular diagnostics for 
most patients. 
In conclusion, we have identified potential therapeutic targets such as ERβ and mTOR pathway 
for inhibiting CSCs. Drugs targeting both CSCs and differentiated cancer cells are promising 
strategies to eradicate cancer recurrences. More clinical trials involving cancer stem cell 
targeting agents along with traditional therapies are required to investigate their clinical 
efficacy. Further, genomic characterization of both primary tumors and metastatic lesions are 
crucial for improving the treatment outcome for advanced breast cancer patients. 
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1 INTRODUCTION 
1.1 BREAST CANCER ORIGIN 
Breast cancer is the most common cancer with more than 255,000 new cases expected in 2017 
in the United States, followed by lung cancer and prostate cancer1. It is the second leading 
cause of cancer related death in women and its incidence rates are further increasing1. Breast 
cancer has been in prevalence since ancient times, it has been reported by Egyptians, more than 
3500 years ago as “tumors or ulcers of the breast”. The normal breast consists of fat, connective 
tissue and mammary tissues with lobes and glands. These lobes produce milk during lactation 
and form a network of milk ducts connecting to the nipple. During breast cancer, epithelial 
cells in the breast tissue grow in an uncontrollable fashion, leading to formation of a lump that 
can either be benign (non-cancerous) or malignant (cancerous). Breast cancers can arise from 
different parts of the breasts: ducts, lobules and in their connective tissues. Malignant cancers 
has the ability to invade and spread to distant organs of the body, a process called metastasis, 
which is the ultimate cause of the death. The exact mechanism by which breast cancer develop, 
is still not well understood. Breast tumors are considered malignant when they start to invade 
and pass through myoepithelial cell layer and basement membrane3. Traditionally, a stepwise 
progression cancer model i.e., from non-to pre- to malignant stages has been proposed, based 
on histopathological examinations in morphological studies4. Many pre-malignant stages has 
been reported in breast cancer development such as hyperplasia, atypical hyperplasia and 
cancer in situ3. However, it has been demonstrated in experimental studies, that the 
development of breast cancer is much more complex than this proposed classical model4. Not 
all pre-malignant lesions leads to breast cancer and many of these lesions are not mandatory 
for breast cancer development4. However, presence of certain pre malignant lesions increases 
the risk of developing invasive breast cancer in later stages of life3. Breast cancer is a complex 
disease featuring multiple clinical, morphological and molecular distinct subgroups5-7. 
Currently breast cancers are broadly divided into non-invasive and invasive cancers based on 
their morphological features8. 
1.1.1 Non-invasive breast cancer 
These type of cancers are also called as carcinoma in situ, of which the most common type is 
called ductal carcinoma in situ (DCIS). DCIS origins from the epithelial cell lining of the milk 
ducts and is referred to as premalignant lesion, since the cancer cells has not yet invaded 
through the basement membrane. Based on cellular morphology, architecture and nuclear 
pleomorphism, DCIS is classified into low, intermediate or high grade and each of them are 
associated with different clinical outcomes9. The developmental mechanisms responsible for 
low and intermediate grade DCIS are proposed to be different to that of high grade DCIS10. 
Genetic studies has identified different alterations between different grades of DCIS11. Lower 
grade DCIS exhibit loss of 16q chromosome, while high grade DCIS often exhibits 17q gain10. 
Consequently, low grade DCIS often advances to low grade invasive cancers, while high grade 
DCIS advances in to high grade invasive cancers. In fact, numerous data indicates that the 
cytonuclear grade of DCIS remains consistent from cancer in situ to invasive cancer and even 
in metastatic disease12. Several genetic aberrations and gene expression patterns that are found 
in invasive breast cancer can be seen already in DCIS4. DCIS itself is not life threatening, but 
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a higher pathological or nuclear grade is often associated with higher probability of invasive 
cancer recurrence13. The second most common type of non-invasive breast cancer is called 
lobular carcinoma in situ (LCIS). LCIS is often considered as risk indicator for invasive lobular 
cancers4. Both DCIS and LCIS are referred as precursor lesions of the breast by WHO-
classifications8. 
1.1.2 Invasive breast cancer 
Invasive breast cancers has the ability to spread to the surrounding normal tissues. The most 
common type of invasive breast cancer is called invasive carcinoma of no special type (NST) 
previously referred as invasive ductal carcinomas not otherwise specified (IDC-NOS)8. Almost 
80% of all breast cancer cases accounts under this morphological category. Invasive carcinoma 
(NST) as well as other subtypes has the ability to spread to nearby lymph nodes and potentially 
to other organs of the body. Invasive lobular carcinoma (ILC) is the second most common type 
of invasive cancers. About 10% of the all invasive cancers are ILC. Together these two types 
of invasive breast cancer accounts for about 95% of all breast cancers in this category. Apart 
from these two invasive breast cancer types, WHO also classifies multiple other entities such 
as tubular carcinoma, medullary carcinoma, invasive papillary carcinoma etc. However their 
incidence rates are much lower compared to the two previously discussed cancer types14. 
1.2 IMMUNOHISTOCHEMICAL ASSESSMENT OF PREDICTIVE AND 
PROGNOSTIC BIOMARKERS 
Apart from the stratifications based on pathological features, breast cancers are also stratified 
based on their expression of estrogen receptor (ERα), progesterone receptor (PR) and human 
epidermal growth factor receptor 2 (HER2). These biomarkers are routinely used in the 
diagnosis and treatment of breast cancer patients. With the available targeted therapies for 
breast cancer, these biomarkers are crucial in identifying patients who will be benefited from 
such treatments. 
1.2.1 Estrogen receptor alpha status 
Hormone receptor status (ERα and PR) is a main factor for management of breast cancer 
patients. Hormones such as estrogen, androgen and progesterone have been shown to stimulate 
cancer cell growth15-17. The hormone stimulatory effect depends on hormone receptor 
expression in breast cancer cells. ERα protein expression in breast cancers are predictive 
biomarker of endocrine therapy response and also associated with good response18. Around 
70% of all primary breast cancers are ERα positive. Currently, protein expression of ERα in 
breast tumors is investigated in the routine pathology setting and predicts response to endocrine 
treatments. In 2010, the American Society of Clinical Oncology (ASCO) and College of 
American pathologists (CAP) set guidelines, with cut off of 1% positive cells to distinguish 
ERα positive from ERα negative tumors, traditionally the cut off was set at 10% of positive 
cells19. In Swedish medical society, 10% cut off is still applied20. Patients with very less ERα 
expression were also shown to be benefited from endocrine therapy21 and ERα negative tumors 
do not respond to tamoxifen treatment at all22. Hormone receptor positive cancers can be 
targeted using three different groups of hormonal therapies, including tamoxifen, aromatase 
inhibitors (AI) and fulvestrant. Each class of endocrine therapy has a different mode of action. 
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Tamoxifen is a selective estrogen receptor modulator (SERM), which blocks the effect of 
estrogen via estrogen receptor (ERα) in breast tissues. Aromatase inhibitors (AI) on the other 
hand reduce the plasma estrogen levels in postmenopausal women by inhibiting or inactivating 
aromatase. Aromatase is an enzyme responsible for the production of estrogens from 
androgenic substrates such as testosterone23. Aromatase inhibitors starves the hormone receptor 
positive cancers, as they are deprived of hormones to grow 24.  
1.2.2 Progesterone receptor status 
Progesterone receptor (PR) is one of the target genes of ERα25. ERα transcriptionally activate 
PR, with the help of estrogen response elements (ERE) present upstream of PR gene25. 
Estrogen treatment of breast cancer cell lines stimulate PR expression and this is often noted 
as a marker for functional ERα signaling25. PR expression strongly correlates with ERα 
expression and therefore believed to predict endocrine therapy response19,22. Prognostic values 
of PR expression has been demonstrated in numerous studies, independent of ERα expression 
and other biomarkers26,27. However, till date, there is no specific approved therapy targeting 
PR in breast cancer.   
1.2.3 HER2 (human epidermal growth factor receptor 2) status 
HER2/neu (ERBB2) is a growth and survival promoting protein expressed on the surface of the 
breast cancer cells28. Traditionally, over expression of HER2 was considered as poor 
prognostic marker, until the first targeted therapy against HER2 was established29,30. HER2 as 
a biomarker has now evolved from being a poor prognostic factor to a therapy predictive 
biomarker29,30. In the absence of targeted therapy against HER2, patients have increased 
mortality and recurrence rate31. About 15% of breast cancers are HER2+ overexpressing 
through gene-amplification32. HER2 status can be determined using immunohistochemistry 
staining or fluorescent in situ hybridization (FisH) technique33. In current scenario, targeted 
HER2 therapies improve patient survival significantly34. However, anti-HER2 therapies has 
been shown to benefit patients only with HER2 overexpression or gene amplification35. Drugs 
such as trastuzumab (Herceptin) and lapatinib are anti-HER2/neu therapies. These therapies 
are not provided to HER2 negative patients.  
1.2.4 Proliferation rate (Ki-67) 
Another important biomarker that pathologists quantify during breast cancer diagnosis is 
proliferation rate. This is measured by manual scoring of mitoses but also Ki-67 using 
immunohistochemistry (IHC) staining36. Although, the function of Ki-67 is unknown, its 
expression is associated with proliferation and ribosomal RNA transcription37. Ki-67 is 
expressed throughout the active cell cycle phase (G1, S, G2 and M-mitosis) and absent in 
resting phase of cell cycle (G0), this makes it a perfect marker for proliferation38.  Number of 
cells positive for Ki-67 directly proportionate to higher degree of proliferation39. Ki-67 has 
been identified as an independent prognostic parameter for disease free survival and overall 
survival in breast cancer patients40. Ki-67 score is used to stratify patients with high or low risk 
of recurrence and as a surrogate marker for differentiating luminal A subtype versus luminal B 
subtype cancers (described in later part), in addition to ER, PR and HER2 statuses41. Variability 
between laboratories, in assessing Ki-67 scores are reported in several studies42. Due to this, 
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no general consensus has been established with regards to the cut-off for Ki-67 for classifying 
patients based on proliferation43. In 2015, the St. Gallen International Expert Consensus 
recommended a cut off of 20% for Ki-67 to classify tumors between luminal-A and luminal-
B44. 
1.3 HISTOLOGICAL GRADE AND STAGE 
Histological grade is determined based on the differentiation levels of individual tumors and it 
is used as an important prognostic factor in breast cancer management. One of the most widely 
validated and used method to determine the differentiation grade of the tumors is the 
Nottingham histological grading system (also referred as Elston-Ellis grade)45. Based on the 
macroscopic examination of morphological and cytological features of cancer cells, three main 
factors are analyzed; degree of tubule formation, nuclear pleomorphism and mitotic count.  All 
three factors are given a score of 1-3 and the scores from all these factors are then combined to 
determine the grade46. Based on the total scores, tumors are then classified into three grades; 
grade 1 (well differentiated, slow growing, total score of 3-5), grade 2 (moderately 
differentiated, total score of 6-7) and grade3 (poorly differentiated, highly proliferative, total 
score of 8-9)46. Grade 1 tumors have good prognosis, while grade 3 tumors have worst 
prognosis46,47. Grade 2 tumors are considered as intermediate group, however their existence 
has been questioned, and some researchers argue that the grade 2 tumors might be a blend of 
grade 1 and grade 3 tumors. Further, grade 2 tumors doesn’t add much of clinically actionable 
information with regards to the therapeutic planning48. The prognostic significance of grade 1 
and grade 3 tumors are clinically relevant while grade 2 tumors which comprises of 
approximately 50% of all breast cancers are not well defined49.  Gene expression and RNA 
sequencing technologies are reported to be better in classifying these grade 2 tumors for 
improving their clinical relevance50,51. 
Staging of breast cancers also provides valuable prognostic information for patients. It is 
determined by TNM classification method52. Primary tumor size (T), spreading of cancer to 
local lymph nodes (N) and distant metastasis (M) are considered in determining the stage of 
the cancer. Broadly breast cancers are classified into stage 0-4, depending on the tumor 
progression state52. Non-invasive tumors such as DCIS and LCIS are stage 0 tumors. Stage 1-
3 tumors are tumors with no distant metastasis and stage 4 tumors are with distant metastatic 
disease. Detailed description of TNM classifications is described well in 7th edition of TNM 
classification manual52,53. 
1.4 MOLECULAR INTRINSIC SUBTYPING OF BREAST CANCERS  
Characterization of breast cancer molecular subtypes is considered as the major breakthrough 
of last decade, in the field of breast cancer classification. Technological advancements in the 
field of high throughput gene expression analysis has made it possible to classify breast cancer 
based on global gene expression. In the seminal work by Perou et al, breast cancers were 
initially classified into five intrinsic subtypes: luminal A, luminal B, HER2 enriched, basal-like 
and normal like5,54. Each of these molecular subtypes was associated with different prognosis. 
These data illustrate that breast cancer exhibit substantial molecular heterogeneity, however 
genetic alterations corresponding to each molecular subtype and their origin is still unknown. 
Molecular subtyping of breast cancer highlighted the need to identify new therapeutic targets 
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for each and every specific subtype. Currently, intrinsic subtype classifications of breast 
cancers is mainly used for research purposes and has a great potential in planning treatment 
and developing new therapies for breast cancer. Below are the most common intrinsic subtypes 
explained briefly: 
1.4.1 Luminal A  
Luminal A is the most common intrinsic subtype, representing 50-60% of total breast cancers. 
At protein level these cancers express ER and PR and are characterized by expressing genes 
involved in estrogen receptor (ER) transcription factor. They also have low expression of 
proliferation genes5,54.  At protein level they do not overexpress HER2 and express very low 
Ki-67. Prognosis for this group of cancers is good. The 15-year distant relapse rate (27.8%) is 
significantly less than other subtypes of breast cancer55. Treatment for this group of patient 
involves selective estrogen receptor modulators (SERM) tamoxifen, fulvestrant or hormonal 
aromatase inhibitors (AI)56.  
1.4.2 Luminal B 
Luminal B cancers make up to 10-20% of all breast cancers. This group of cancers are more 
aggressive than Luminal A cancers. They have high histological grade and proliferation rate in 
turn correlating to worse prognosis. Although luminal A and the majority of luminal B express 
ERα, luminal B prognosis is very different from luminal A. This is because luminal B cancers 
have higher expression of proliferation associated genes such as Ki-67, cyclin B1 and growth 
factor genes such as EGFR and HER25. Identification of biomarker specific to luminal B is 
crucial to understand the biology of these cancers and eventually design targeted therapy 
against it. Ki-67 is been currently used as a biomarker to differentiate luminal A from luminal 
B cancers57. The cut-off level of Ki-67 to divide the Luminal tumors into distinct groups is not 
yet standardized worldwide, leading to variability while assessing Ki-67 as biomarker. IHC of 
biomarkers (ER/PR/HER2/Ki-67) has been used as surrogates for determining molecular 
subtypes. Luminal A has been defined as ER+/and/or PR+/HER2-/Ki67<20%, while luminal 
B tumors as ER+/and/or PR+/HER2-/Ki67>20% or ER+/and/or PR+/HER2+/Ki67 any44. 
Luminal B cancers are also treated with tamoxifen or AI, however their response rate is poor58.  
Hence, they also receive chemotherapy. They often respond to chemotherapy (17%), however 
this response rate is probably lower than for HER2-enriched and basal-like cancers (36% and 
46% respectively)59, for this reason treatment for luminal B cancers are challenging and much 
effort needed to find new pathways involved to target them. 
1.4.3 HER2-enriched 
This group of cancers are characterized by having high expression of the ERBB2 (HER2) gene 
located in the 17q12 chromosome. HER2-enriched cancers constitute about 15-20% of all 
breast cancers. These cancers express low levels of luminal genes and their IHC profile are 
defined as ER-/HER2+. Only 70% of tumors classified as HER2-enriched subtype by gene 
expression have an over expressed HER2 protein59,60. Moreover, not all HER2 amplified or 
overexpressing tumors falls under the HER2-enriched intrinsic category. Depending on the ER 
status, if IHC profile is ER+/HER2+ the tumor is classified as luminal B. Based on the 
pathological characteristics (usually high histological grade), these tumors are highly 
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proliferative and have poor prognosis. However, targeted anti-HER2 therapies such as 
trastuzumab has been substantially developed during last decade, improving the survival of 
patients with both metastatic and primary cancers61.  
1.4.4 Basal-like 
About 10-20% of all breast cancers are basal-like. Basal like cancers are characterized by high 
histological grade, high frequency of lymph node infiltration, large tumor size at diagnosis, 
high rate of p53 mutations and occurs frequently in women of African origin54,62. The IHC 
profile of these cancers is defined as ER-/PR-/HER2-; therefore in clinical terms it is also 
referred as triple negative (TN) cancers. However, not all triple negative cancers are basal-like 
cancers and there is a discordance of 30% described between these two groups63. Basal-like 
cancers have poor prognosis compared to luminal groups54,64 and the metastatic relapse sites 
are predominantly in visceral organs such as lung and central nervous system55,65. Although 
basal-like cancers have higher response rates to chemotherapy than luminals66, basal-like 
subtype have higher relapse rate during the first 3 years67. Germline mutation in BRCA1 gene 
give rises to sporadic breast cancers, which falls under basal-like subtype64. The BRCA1 gene 
is involved in DNA damage repair mechanism, which inspired the need to target this 
mechanism for future therapies for basal-like cancers. The poly-ADP ribose- polymerase-1 
(PARP-1) is a key molecule in single strand DNA break repair system. PARP-1 inhibitors are 
becoming a promising strategy in BRCA1 mutated patients, leading to accumulation of double 
stranded DNA breaks causing cell death68. 
1.4.5 Normal-like 
Normal-like intrinsic subtype of breast cancer occurs rarely, about 5-10% of all breast cancers 
are believed to come under this intrinsic group. Their gene expression profile groups under 
fibroadenomas and normal breast samples5, hence the term normal-like. These cancers are also 
ER-/PR-/HER2- (TN) with intermediate prognosis, placed between luminal and basal-like. The 
difference between normal-like and basal-like cancers is that normal-like cancers do not 
express cytokeratins and EGFR69,70. Some researchers are skeptical about their real existence, 
as they believe it might be a technical artifact in microarray technology, which includes normal 
breast tissue contamination in cancer samples which contributes to this intrinsic subtype71. 
Since this intrinsic subtype is rare, very few studies are reported about this group and the 
clinical significance of this subtype is yet to be determined. 
1.4.6 Claudin-low 
Claudin-low intrinsic subtype has been identified in later studies72. The term claudin-low was 
coined due to its characteristic low expression of genes involved in intercellular adhesion and 
tight junctions such as claudin-3, 4, and 7 and E-cadherin. This subtype of cancers clusters 
together with basal-like subtype, with low HER2 and luminal genes, however claudin-low 
subtype over expresses a set of immune response genes (40 genes) suggesting an increased 
immune infiltration in this type of cancers59,73. Although this subtype has low expression of 
proliferation associated genes, they have poor long-term prognosis73. This might be because 
they overexpress another set of genes involved in mesenchymal differentiation and epithelial-
mesenchymal transition (EMT). These features are related to acquiring cancer stem cell (CSC) 
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phenotype which are implicated in tumor progression and metastasis74. IHC profile of claudin-
low subtype is normally TN, however 20% of them are hormone receptor positives60.  
Certain expert panels like The St. Gallen International Expert Consensus for Early Breast 
Cancer 2015 has recommended molecular profiling of breast cancers to be included in 
treatment planning process for breast cancer. This expert panel states five clinico-pathological 
defined groups; luminal A (ER+/and/or PR+/HER2-/Ki67<20%), luminal B (ER+/and/or 
PR+/HER2-/Ki67>20%) or (ER+/and/or PR+/HER2+/Ki67 any), HER2 enriched (ER-/PR-
/HER2+) and triple negative (ER-/PR-/HER2-)44. Uncertainty still persist with regards to the 
intrinsic subtype classification between luminal A and luminal B for intermediate Ki-67 
expression group (Ki-67 levels of 10-35%)44. In short, luminal A cancers are treated only with 
endocrine therapy. Endocrine therapy combined with chemotherapy is recommended for 
luminal B. Anti-HER2 therapy combined with chemotherapy for HER2 enriched and only 
chemotherapy for Triple negative cancers75.  
 Luminal A Luminal B HER2 + Triple negative 
(Basal like) 
Percentage at 
diagnosis 
40-50%  15-20% 10-15% 15-20% 
Receptor 
expression 
Estrogen (ERα) and/or progesterone (PR)   
 HER2 + 
Proliferative index Low Ki67 High Ki67 Usually high Ki67 Usually high Ki67 
 
Treatment 
strategies 
Chemotherapy 
 HER2 targeted therapies  
Hormonal therapies   
Novel targeted therapies 
Table 1. Breast cancer subtypes defined by histology and immunohistochemistry. Different 
tumor characteristics for ER, PR, HER2 and Ki67 within established intrinsic subtypes. The 
normal like and claudin low have been omitted. Adapted from Norum et al.201476 
1.5 INTRA-TUMOR HETEROGENEITY IN BREAST CANCER 
Intra-tumor heterogeneity signifies the existence of subpopulation of cancer cells that differ in 
their genetic, epigenetic and biological make up within a tumor. Massive parallel sequencing 
studies of primary breast cancers have demonstrated that both spatial and temporal 
heterogeneity are common within a tumor77-80. Specific driver gene aberrations such as HER2 
amplifications, TP53 and P13KCA somatic mutations are reported to be heterogeneous with in 
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neoplastic cells in primary tumors81,82. Furthermore, it has been demonstrated that individual 
breast cancers have distinct subpopulation of cancer cells across different region of the same 
tumor (spatial heterogeneity)77,83 or cancer cells genetically evolve over time between primary 
tumors and subsequent recurrences (temporal heterogeneity)79.  
Currently, there are two theories to explain why we observe intra tumor heterogeneity in 
cancers 1) the cancer stem cell hypothesis and 2) the clonal evolution model84. In recent years 
it has been perceived that these two models are complimenting each other and they might not 
be mutually exclusive as previously thought85. Both models propose that cancer originate from 
a single cell with abnormal genomic aberrations leading to indefinite proliferative phenotype 
and tumor microenvironment can impact cellular composition of tumors. However, the main 
difference between these two models is the support for existence of cellular hierarchical 
organization by CSC model. According to CSC model, intra tumor heterogeneity is attributed 
to deregulation of the differentiation process of CSC’s and proposes the existence of a 
hierarchical organization of cancer cells, where cancer stem cell (CSC) are at the apex  of the 
hierarchy. These CSCs are considered as a minor subset of cells in a tumor which are lineage 
committed progenitor  cells, which can give rise to more differentiated cancer cells86. This 
model also proposes that the tumor growth and disease progression is governed by this small 
subset of cells with stem cell features (CSC), while the rest of the bulk tumor cells do not 
contribute to tumor growth87. This hypothesis however, being disputed, since evidence 
illustrating the existence of a dynamic interconversion between differentiated cells and CSCs 
via epithelial mesenchymal transition (EMT) process has been reported88. Therefore, in some 
cancers CSC phenotype might represent only a ‘”state of stemness” which, cancer cells within 
a tumor can attain rather than being a distinct hierarchical based subset of cells. The clonal 
evolution model on the other hand attribute the observed intra-tumor heterogeneity as a 
Darwinian evolution of cancer cells, where the cancer clones that would survive tumor micro-
environmental conditions and treatment pressure propagates further leading to therapy resistant 
clones89,90. Unarguably, it is evident that breast cancers exhibit high degree of phenotypic and 
genetic intra-tumor heterogeneity, this might have direct impact on both diagnosis and disease 
management.  
1.6 BREAST CANCER THERAPEUTICS TARGETING MAJOR SIGNALING 
PATHWAYS 
With our previous knowledge of molecular intrinsic subtypes of breast cancer, we can clearly 
understand that breast cancer is a heterogeneous disease. Each molecular subtype harnesses a 
distinct growth stimulatory advantage91. Recent technological and experimental developments 
have provided more insights on cellular process and pathways involved in the development of 
breast cancer. Several signaling pathways are implicated in breast cancer development 
affecting cellular process such as cell survival, proliferation, migration, differentiation and 
apoptosis92-94. These signal transduction pathways frequently cross-talk between each other to 
ensure breast cancer cells responds appropriately to the extracellular growth factors. Slow and 
gradual disruptions of these signaling pathways provided the growth advantage to the cells 
leading to cancer later on. In this thesis, we will discuss the most common signaling pathways 
targeted in breast cancer treatment.  
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1.6.1 Estrogen receptor signaling 
Estrogen receptors (ERs) are ligand regulated transcriptional factors which transduce hormonal 
signals in various organs for variety of physiological responses95. There are two estrogen 
receptors; ERα and ERβ, products of two different genes on two chromosomes and are 
structurally similar but differentially expressed in tissues. ERs regulate cell proliferation and 
differentiation in normal mammary gland in an estrogen dependent fashion by both canonical 
genomic and non-genomic transcriptional mechanisms96. In response to estradiol binding, ERα 
undergo conformational change which controls its interactions with other co regulators, leading 
to its binding to the estrogen response element (ERE) within the promoter of target genes. ER-
dimerization upon E2 stimulation, recruits other co-regulators involving chromatin 
remodeling, which enhances the transcriptional activity97. E2 bound ERα complex alter the 
transcription of genes involved in proliferation, differentiation, survival and pathways crucial 
for cancer such as invasion, metastasis and angiogenesis98. Estrogen also signals through non-
genomic pathways via membrane ER99 and trans-membrane G-protein-coupled receptor 
complexes (GPCR)100. ER mediated transcription is a complex process involving many co-
regulators and cross-communication between different signaling pathways and has been well 
described in detail in other review articles101. In short, growth of ER+ cancer cells are E2 
dependent and the removal of E2 can reduce their growth, therefore ERα is a well-established 
predictive marker of hormone sensitivity. Currently luminal BCs are treated with SERMs and 
also with aromatase inhibitors which can improve the overall survival by almost 50% during 
the period of first 5 years22.  Extending this endocrine therapy to 10 years has also shown to be 
more beneficial22. However, the response is often not permanent and certain patient become 
resistant to endocrine therapy102.  
Another important signaling axis, which is closely linked to estrogen signaling is cyclin D1-
CDK4/6 (cyclin dependent kinases)-Rb (retinoblastoma protein) pathway. Hyper 
phosphorylation of Rb by CDK/cyclin D1 is crucial for G1-S transition during cell cycle103,104. 
Estrogen stimulated MCF7 cells induce cyclin D1 gene activity followed by CDK4 activation 
and Rb phosphorylation105,106. Overexpression of cyclin D1 renders breast cancer cells to be 
endocrine resistant107. Inhibiting cyclin D1-CDK 4/6-Rb pathway is a novel potential 
therapeutic target in luminal breast cancer108. Palbociclib, a CDK4/6 inhibitor was recently 
approved by FDA for use in combination with endocrine based (in combination of letrozole-
aromatase inhibitor) therapy for metastatic disease in post-menopausal women with ER+, 
HER2- advanced breast cancer109. Palbociclib in combination with letrozole, reported an 
improvement in progression free survival (PFS) from 10.2 months (only letrozole treatment 
group) to 20.2 months (combination treatment group) in a large phase 2 study109.  
1.6.2 EGFR (Epidermal growth factor receptor) and HER-2 
Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase 
glycoprotein (170kDa) belonging to the ErbB family. This family of proteins are activated 
aberrantly in various human cancers including breast cancers110. The ErbB family contains four 
proteins: Epidermal growth factor receptor (EGFR/HER-1/ErbB-1), Human epidermal growth 
receptor HER-2 (ErbB-2), HER-3 (ErbB-3) and HER-4(ErbB-4)111. There are three main 
functional domains in these receptors: a ligand binding, a hydrophobic transmembrane and a 
cytoplasmic tyrosine-kinase domain. Ligand activation of EGFR, leads to homo or hetro-
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dimerization (with other family member receptors) and subsequent auto phosphorylation of 
tyrosine kinase domain which in-turn activates downstream signaling pathways such as 
MAPK/ERK, PI3K/AKT, STAT (signal transducer and activator of transcription) pathways112-
114. 
HER-2 appears on the surface of some of the breast cancers115. Overexpression of this protein 
and activation of its downstream signaling pathway has in fact lead to separate molecular 
intrinsic subtype of breast cancers namely “HER-2 enriched” which has been described earlier 
in this report highlighting the importance of this molecule in breast cancer. Around 15% of 
breast cancers overexpress HER-2 protein by genomic amplification, which makes cancers 
more aggressive28, and has the potential to spread to other body parts116. Over expression of 
HER2 leads to homo or hetro-dimerization (with other family members), eventually 
phosphorylating tyrosine residues on each other117. HER-2 transduces its function mainly via 
PI3K/AKT118 and Ras/MAPK signaling pathway 119. Activation of HER-2 upregulates 
expression of anti-apoptotic proteins such as survivin and Bcl-2 in cancer cells120. Targeting 
HER-2 Signaling is beneficial to patients with aberrant HER-2 activation. Drugs like 
tratuzumab, pertuzumab and lapatinib are specifically targeted against HER-2121. 
1.6.3 PI3K/AKT pathway  
Another important signal transduction pathway, which is often deregulated in many human 
cancers, including breast cancer is PI3K/AKT pathway118. The PI3Ks are lipid kinases, whose 
function is to phosphorylate phosphoinositides122. Class IA PI3Ks comprise of two 
components; a regulatory subunit (p85) and a catalytic subunit (p110). Growth factors or 
ligands binding to their respective receptor tyrosine kinases (RTK) such as EGFR, HER-2 and 
IGF-1R initiates P13Ks. Upon receptor activation, p85 subunit of PI3K interact with the RTK’s 
intercellular domain, which activates p110 catalytic subunit of P13K. Activated P13K 
phosphorylates phosphatidylinositol bisphosphate (PIP2) to phosphatidylinositol trisphosphate 
(PIP3). AKT, a serine/threonine kinase docks to PIP3, which is the central effector of this 
pathway. Phosphorylated AKT stimulates protein synthesis and cell growth by inducing 
mammalian target of rapamycin (mTOR)122. AKT increases anti-apoptotic proteins such as 
Bad, and promotes cell cycle proteins such as c-Myc and cyclin D1 and decreases cell cycle 
inhibitors such as p27 and p21, resulting in boosting cell survival. This pathway is crucial for 
many cellular process such as cellular metabolism, cell survival, proliferation, differentiation, 
cancer progression and motility123. mTOR is a key mediator of cellular response to multiple 
stimuli such as cellular nutrients and growth factors. In response to these stimuli, mTOR 
activates the translational machinery leading to the enhanced mRNA translation of genes 
involved in cell growth and cell progression124. Phosphatase and tensin homologue (PTEN), is 
an intrinsic negative regulator of PI3K/AKT pathway. PTEN converts PIP3 back to PIP2, 
thereby inhibiting the further signaling cascade of PI3Ks. Uncontrolled activation of 
PI3K/AKT/mTOR pathway (can be either genomic or epigenetic alterations) contributes to the 
establishment and progression of many human cancers including breast cancer125.  In breast 
cancers, majority of activating mutations occur at the catalytic subunit (p110 α) of PI3Ks, 
which increases the enzymatic activity of PI3K in a ligand independent manner thereby 
contributing to the oncogenic transformation. About 20%-25% of all breast cancers, depending 
on their intrinsic subtype have PI3K mutations. It’s interesting to note that, luminal breast 
cancers have higher frequency (>30%) of these mutations in PI3K than triple negative breast 
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cancers (5%)126. Further, loss of PTEN is also reported in breast cancer but with much lower 
frequency. Activating mutations in PI3Ks and loss of PTEN confers resistance to the anti-
receptor therapies such as trastuzumab against HER-2127. Therefore, this pathway is a potent 
target for anticancer agents. Several clinical trials are currently ongoing targeting mTOR 
(ClinicalTrials.gov: NCT00876395, NCT01698918, NCT01783444 etc.,) and PI3Ks/ AKT 
inhibitors such as buparlisib is in phase 3 clinical trials (ClinicalTrials.gov; NCT01610284, 
NCT01082068 etc.). Everolimus (mTOR inhibitor) is now approved for post-menopausal 
women with advanced metastatic breast cancer (ER+ and HER2-) in combination with 
endocrine therapy (exemestane) as this combination significantly improves the progression free 
survival in these patients128. 
1.6.4 PARP signaling pathway 
Poly (ADP-ribose) polymerase 1 (PARP-1) is a critical molecule involved in DNA repair and 
apoptosis process 129. PARP is responsible for recognizing single strand DNA breaks and 
repairs it via base excision pathway130 and also bind to double stranded breaks preventing 
accidental recombination of homologous DNA131. In wild type cells, the double stranded 
breaks often repaired via homologous recombination with the help of BRCA1 and BRCA2 
proteins132. However, cells deficient with BRCA1 and BRCA2 are unable to repair the double 
stranded DNA breaks leading to chromosomal instability, cell cycle arrest and subsequent 
apoptosis133. Hence PARP inhibitors have shown efficacy in breast cancers with BRCA1 or 
BRCA2 inherited mutations68. PARP inhibition is a recently developed strategy which exploits 
the DNA damage response pathway in cancer cells134. Enhanced PARP-1 expression has also 
been observed in triple negative breast cancers133. PARP inhibitors such as olaparib, veliparib 
and iniparib have shown promising anti-cancer response for breast cancer and are currently 
validated in clinical trials. PARP inhibitors in combination with inhibitors of AKT or mTOR 
are also under clinical trials (ClinicalTrials.gov; NCT02338622 and NCT02576444).   
1.6.5 Angiogenesis 
Angiogenesis is a complex and dynamic process involving formation of new blood vessels. It 
has been widely accepted that, cancer cell growth and proliferation is dependent on 
angiogenesis for tumor development and progression. Angiogenesis plays a crucial role in both 
primary breast cancer development and in metastasis135. Hypoxia is a key switch for the 
induction of the angiogenesis process. Under hypoxic conditions, HIF1- α (transcription factor) 
is stabilized and transcribes genes involved in the angiogenesis process136. Six different pro-
angiogenic factors have been identified to be commonly expressed in invasive breast cancers, 
with vascular endothelial growth factor (VEGF) being the predominant one137. The VEGF and 
PDGF (platelet-derived growth factor) family of proteins and their receptors (VEGFR-1, 
VEGFR-2, VEGFR-3, PDGFR-α and PDGFR-β) seems to be the central players of 
angiogenesis process138. Signal transduction via VEGFRs and PDGFRs initiate many cellular 
process such as survival, mitogenesis, migration and differentiation138,139. Numerous studies 
have found an inverse correlation between VEGF expression and overall survival (OS) in both 
lymph node-positive and negative breast cancers140,141. Advanced breast cancers expressing 
higher VEGF are less responsive to chemotherapy and endocrine therapy142. A fraction of 
invasive breast cancers which over–expresses PDGFR-α have been associated with more 
aggressive phenotype with increased metastatic potential143. Due to their important role in 
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tumor angiogenesis process, VEGF and PDGF are the key targets for experimental breast 
cancer treatment. Although the implication of angiogenesis is prominent in tumor biology, 
targeting angiogenesis is often challenging as it requires inhibition of more than one receptors 
to block angiogenesis. It has been proposed that, anti-VEGF therapy can perform two important 
functions; first, it can block the development of new tumor vasculature resulting in tumor 
regression, second, it can normalize the existing inefficient tumor vessels thereby supporting 
drug delivery into the tumor144. For this reason, anti-angiogenic therapy has potential when 
combined with chemotherapy144,145. Several anti-angiogenic therapies has been developed in 
recent years. For example: monoclonal antibodies such as bevacizumab (avastin) which binds 
to VEGF, thereby reducing the VEGF content from the circulation, subsequently preventing 
the activation of VEGFRs146. This drug was approved by FDA for the treatment of multiple 
different cancers such as non-small-cell lung, colorectal, renal cell, glioblastoma and breast147. 
In breast cancer however, data from multiple clinical trials have shown that, the effect of 
bevacizumab in improving progression free survival was modest with some adverse side 
effects147,148. Consequently, FDA has removed bevacizumab’s approval for treatment of HER2 
negative metastatic breast cancer147. However, it is still approved by European medicine 
agency (EMA). More development and validations of biomarkers are necessary to identify 
patients who will benefit from angiogenesis based therapies. 
 
Figure 1: Key signaling pathways and their potential inhibitors involved in breast cancer. (E2 
estradiol, TKI-Tyrosine kinase inhibitor, moABS-monoclonal antibodies, AI-Aromatase 
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inhibitor, SERMs-Selective estrogen receptor modulators, ER-estrogen receptor, DSB-double 
stranded DNA break. 
1.7 BREAST CANCER DRUG RESISTANCE 
Drug resistance is one of the main challenges in the treatment of breast cancer. Breast cancer 
cells acquire resistance to both chemotherapeutics (taxanes and anthracyclines) as well as 
targeted therapies (anti-HER2, tamoxifen and anti-VEGF). Some patients possess cancers, with 
innate resistance to chemotherapy and do not respond, other patients have tumors with partial 
response, in such cases only a fraction of tumor cells are killed during chemotherapy149,150. The 
remaining fraction of cells continues to grow and establish recurrent tumors. Gain of de novo 
resistance during chemotherapy (also referred as “acquired resistance”) were also reported in 
breast cancers151,152. Many biochemical and cellular mechanism have been proposed for drug 
resistance. In this thesis, we will discuss only about endocrine resistance in breast cancer cells.   
1.7.1 Endocrine resistance in breast cancer 
Majority of the breast cancers are ERα positive (70-75%). Tamoxifen, a SERM is the mostly 
widely used endocrine therapy against ER positive breast cancers for both pre-menopausal and 
post-menopausal patients153. Tamoxifen is a partial antagonist of ERα, as it competes with 
estrogen for ERα receptor binding and impairs its function154. Tamoxifen as adjuvant therapy 
in early breast cancer patients improves overall survival of patients and has significantly 
lowered the breast cancer mortality over the last decade in luminal breast cancer patients155,156. 
Further tamoxifen has been reported as a potential preventive agent against hormone dependent 
breast cancer157. Despite the good response rate of tamoxifen, around 40% of patients receiving 
tamoxifen as adjuvant therapy eventually relapse with tumors158. Loss of ERα expression in 
recurrent tumors might be one of the reasons for the poor endocrine response2,159. Aromatase 
inhibitors (AI) are another class of endocrine drugs which prevents the conversion of androgens 
to estrogens, thereby reducing the plasma estrogen levels in the body23. It has been reported 
that, AI are more efficient than tamoxifen in reducing cancer recurrences160, however they are 
provided only to post-menopausal women since, ovaries in pre-menopausal women can 
produce estrogen and neutralize the effect of AI161. Further, use of AI is associated with higher 
risk for osteoporosis compared to tamoxifen, however it has reduced risk of thromboembolic 
events162. Despite the efficacy of AI therapy, around 20% of patients relapse later in their life22. 
Intrinsic resistance and acquired resistance to endocrine therapies is a major challenge in 
treating hormone dependent breast cancers. Understanding the biological mechanisms behind 
this resistance will hopefully provide us with novel biomarkers associated with resistance and 
improved breast cancer treatments. 
ERα expression is the routine prognosticator of tamoxifen treatment155. PR expression is also 
used to increase the accuracy of predicting endocrine therapy response, as it represents 
functional ER pathway and estrogen dependence in luminal cancers159.  Loss of ERα expression 
and its function has been reported as the main mechanism for de novo resistance to 
tamoxifen163. Few patients with ERα-positive cancers will relapse with a metastatic disease, 
which do not express ERα164. However, majority of resistant patients still do express ERα 
during disease progression. Acquired mutations in ERα may lead to functionally negative ERα 
phenotype in spite of ERα expression165. In fact up to 20% of patients with tamoxifen resistant 
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recurrent cancers, still respond to aromatase inhibitor or fulvestrant, suggesting functional ER 
regulation in the tumor growth of these tamoxifen resistant patients166,167. Alterations in 
pharmacological tolerance of tamoxifen has also been reported to cause tamoxifen 
resistance168. Transcriptional co-activators and co-repressors play an important role in 
transcriptional activation of ER. Alterations in co-regulatory proteins such as AIBI has also 
been reported to cause a tamoxifen resistant phenotype in breast cancer169.  A number of studies 
demonstrate that, cross-talk between ER signaling and other growth factor receptor signaling 
pathways, such as insulin-like growth factor receptor (IGFR) and EGFR/HER2, as an important 
endocrine resistance mechanism. Ligand bound ER can activate IGFR directly at the cell 
membrane leading to the downstream ERK1/2 MAPK signaling cascade170. Membrane bound 
ERα is also reported to interact directly with HER2 and also activates EGFR by 
phosphorylation171. Cell-lines under the constant hormonal therapy such as tamoxifen and 
fulvestrant, acquire resistance to these drugs by overexpressing HER2/EGFR signaling 
pathways and these resistant cells are sensitive to EGFR inhibitors172. Induction of growth 
factor receptor signaling during tamoxifen treatment may cause loss of hormone dependence 
and in turn lead to reduced sensitivity to tamoxifen in breast cancers. ER signaling also seems 
to cross-talk with P13K/AKT signaling pathway which is involved in proliferation and anti-
apoptotic responses. ERα can bind to p85 subunit of P13K in a ligand dependent manner, 
thereby activating P13K/AKT downstream effectors99. Relationship of ERα with P13K/AKT 
pathway is reciprocal, activated P13K, activates AKT, which phosphorylates ERα at serine-
167, resulting in ligand independent activation173. Another growing field of research in 
therapeutic resistance, focuses on cancer stem cells, however their role in endocrine resistance 
is not yet well understood.  
1.8 BREAST CANCER STEM CELLS (BSCS) 
The idea of small population of cancer cells with self-renewal capabilities are referred as cancer 
stem cell (CSC) or cancer initiating cells (CIC), which is believed to be responsible for cancer 
initiation and maintenance. CSC hypothesis was postulated long time back, however 
conclusive evidence of their existence was obtained relatively recently in human leukemic 
developmental process174. Majority of the breast cancer treatment fails due to the tumor 
evolution leading to metastasis and chemotherapy resistant disease. This highlights the 
possibility of a fraction of cancer cells with stem cell-like characteristics, which are resistant to 
chemotherapy and radiotherapy175, could be the cause of cancer recurrence and progression176. 
The definitive existence and characterization of CSC are not yet fully validated in majority of 
human malignancies. Currently, CSCs are identified using three main characteristics: 1) 
expression of cell surface markers associated with stemness; 2) the capability to grow in non-
adherent conditions, resistant to anoikis (apoptosis induced during loss of cell-matrix 
detachment) and without serum; 3) the ability to self-renew and can rebuild the heterogeneity 
of the original tumor via differentiation process in xenograft models177,178.  
In breast cancer, CSCs were initially identified using cell surface markers characterized by 
CD24-/low/44+/high. They were highly tumorigenic and a few hundred cells were enough to form 
an heterogeneous tumor, representing the parental tumor when inoculated in NOD/SCID 
mice179. Since, breast cancer stem cells (BSC) are resistant to anoikis (apoptosis induced during 
loss of cell-matrix detachment), they can be isolated and propagated as mammospheres in non-
adherent culture conditions (without serum and supplemented with growth factors)178. CSCs 
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can be isolated from patient derived tumors178 as well as from breast cancer cell lines180. 
Although the combination of CD24-/44+ are important markers for BSC isolation, only a 
fraction of these cells were highly tumorigenic, highlighting the need for more markers to 
represent true BSC. The enzymatic activity of aldehyde dehydrogenase (ALDH1) was reported 
to be associated with tumor initiating breast cancer cells181. ALDH1 has been previously 
reported as stem cell marker in hematopoietic, lung and colon cancers182,183. There is only a 
partial overlap between the ALDH1+ and CD24-/44+ cells, the small population of cells which 
are identified by combing all these markers ALDH1+ and CD24-/44+ are proven to be even 
more tumorigenic than other sub-populations, only 20 cells were sufficient to form tumors 
when xenografted to NOD/SCID mice181. Gene expression analysis identified that ALDH1High 
cells were linked with more epithelial genes, while CD24-/44+ cells were associated with 
mesenchymal-related genes. This suggests that BSC population can be composed of two 
different subsets of cells; 1) CSCs with mesenchymal-like phenotype (for invasion and 
metastasis) and 2) CSCs with epithelial-like characteristics (for tumor growth). Numerous 
publications has reported that BSCs are capable of switching between epithelial-like state to 
mesenchymal-like state and vice-versa which drives them to colonize distant site and form 
metastasis184. Interestingly, it has been shown that BCSs share similar DNA alterations 
compared to the bulk tumor cells highlighting the importance of differentiation and de-
differentiation between CSCs and tumor cell population during cancer progression185. BSCs 
are shown to express gene signatures similar to cells subjected to epithelial to mesenchymal 
transition (EMT) process186. This process is crucial for cancer invasion, as the percentage of 
BCSs are higher in metastatic lesions187. Pathways active in CSC maintenance and self-renewal 
processes such as Notch, Wnt and Hedgehog signaling pathways are induced in EMT process 
as well188,189.  
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Figure 2: Schematic representation of cancer recurrences using conventional therapy versus 
combination therapy (targeting CSCs + conventional therapy). 
1.8.1 CSC resistance to anti-cancer therapeutics 
Current cytotoxic anti-cancer drugs target rapidly proliferating cells and spares the quiescent 
cells with stem cell characteristics. This has been shown by the increased number of CD24-/44+ 
stem-like cells in residual tumor after chemotherapy190. In another study, researchers have 
demonstrated that letrozole and docetaxel treatment on different molecular subtypes of breast 
cancer induced CD24-/44+   molecular signatures191. BSCs were also shown to be resistant and 
increased in numbers after radiotherapy192 and this effect can be attributed to two explanations; 
First, BSC’s ability to generate reactive oxygen species is impaired193 and second, Wnt 
pathway signaling in BSCs may mediate this response194. A few suggested mechanisms by 
which CSCs can intrinsically resist chemotherapy are summarized below: 1) CSCs are in 
quiescent state and maintain low proliferation rate195, 2) CSC over express anti-apoptotic 
proteins such as bcl-2 and other growth factor signaling essential for the stemness phenotype196, 
3) CSCs express high amounts of drug efflux mechanism related proteins, which helps to 
decrease the amount of drugs retained in the cells197, 4) increased efficiency of DNA repair and 
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alterations in cell cycle regulators, thereby rendering CSCs resistant to traditional radiation and 
cytotoxic compounds198.   
1.8.2 Current strategies to target CSCs 
1.8.2.1 CSC’s self-renewal pathway inhibition 
Self-renewal is one of the most important properties of CSCs to maintain their proliferative 
capability. Self-renewal pathways play a crucial role in normal stem cells during early 
developmental stages to determine cell proliferation, differentiation, cellular fate and polarity. 
These self-renewal pathways are therefore strictly regulated.  In CSCs however, self-renewal 
pathways are deregulated leading to increased cell proliferation and this is considered as early 
stages of tumorigenesis199. Notch, Wnt and Hedgehog (Hh) pathways are implicated in 
maintaining self-renewal capabilities of both normal and cancer stem cells in the breast200. 
Evidences suggest that these pathways are deregulated in many human breast cancers201,202 and 
deregulation of these pathways in transgenic mice models leads to the onset of breast 
cancers203,204.  
Four transmembrane Notch receptor proteins (Notch 1-4) are present in mammals. Ligands 
binding to these Notch receptors can activate Notch signaling205, which can further downstream 
induce expression of Hey, cyclin D1, c-Myc and Hes206. Activated Notch signaling increase 
the mammosphere forming efficiency of normal mammary stem cells and can be inhibited by 
using specific notch inhibitors207. In another study, Notch-4 activity was found to be increased 
significantly in BSC population and it can be inhibited using Notch-4 specific inhibitor in breast 
cancer cell lines208. Antibodies against Notch-1 and Notch-4 can decrease mammosphere 
forming efficiency from patient derived BSCs and PDX models209,210. Currently, Notch 
inhibitors such as γ secretase have entered clinical trials, where these compounds are combined 
with existing cytotoxic agents211,212.  
Hedgehog pathway (Hh) is involved in developmental of normal mammary gland. Hh pathway 
via paracrine signaling can induce progenitor cell proliferation in the mouse mammary 
gland213. Other similar studies, also reported that activation of Hh signaling can promote 
mammosphere forming capacity of normal mammary stem cells, while treatment with Hh 
inhibitor (cyclopamine) can inhibit this process214,215. In patient derived BSCs, Hh signaling 
was found to highly activated214 and activation of Hh signaling induced mammosphere 
formation in cells derived from mouse (p53-null) mammary tumors216. In a recent study, Hh 
pathway was found to be associated with poor prognosis in breast cancer patients with the 
CD24-/44+   phenotype217. In addition, Gli1, which is one of the main components of Hh 
signaling was found to initiate triple negative breast cancer218. These findings suggest that, 
targeting Hh pathway is one of the ways to target BSCs. Several compounds are currently being 
tested for utilizing Hh signaling for targeting CSCs212. In addition to Notch and Hh pathways, 
Wnt/β catenin signaling pathway was also demonstrated to be crucial of BSC survival and its 
inhibition suppresses breast cancer metastasis by inhibiting CSC-like phenotype219.  
1.8.2.2 HER2/P13K signaling in CSCs 
Apart from stemness specific self-renewal pathways, HER2 signaling, PI3K/AKT/mTOR and 
JAK2/STAT3 pathways are also involved in BSCs maintenance and drug resistance220-222.  In 
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recent years, anti-HER2 therapy in adjuvant setting reduced the tumor recurrence 
significantly223. It could be possible that, the remarkable clinical efficacy of trastuzumab (Anti-
HER2 therapy) might be due to the fact that it targets BSCs as well. For instance, use of 
traditional chemotherapy increased the CSC population, while combination of anti-HER2 
agent such as lapatinib and chemotherapy reduced CSC population220. Further, this study 
demonstrated a positive correlation of ALDH1 expression (a stem cell marker) and HER2 
amplification in breast cancers. Cells over expressing HER2 also increased CSC population 
with high invasive potential220. Unfortunately, 50% of the patients who initially respond to 
HER2 therapy, develop resistance and relapse127. The mechanism behind resistance to HER2 
therapy is still not clear, however few mechanisms such as hyper-activation of the downstream 
pathway such as P13K/AKT and loss of PTEN (tumor suppressor gene) are partially held 
responsible for this127. Therefore, inhibiting pathways downstream of HER2 signaling can also 
potentially target the CSC population. One such AKT targeting agent called perifosine has been 
shown to effectively reduce BSCs in xenografts224. In another study, it was demonstrated that 
targeting both Notch and HER2 signaling was crucial for prevention of HER2 positive 
recurrences225.  
1.8.2.3 CSC microenvironment inhibition 
Apart from the intracellular self-renewal signaling pathways, tumor microenvironment also 
influences BSCs. Tumor microenvironment of BSCs also referred as “CSC niche” often consist 
of differentiated tumor cells, inflammatory cells, fibroblasts, endothelial cells and 
mesenchymal stem cells226. The interaction of these different stromal cells with the CSC is 
governed via paracrine signaling. This paracrine signaling often results in activation of 
previously described self-renewal pathways of CSCs such as Wnt, Notch and Hedgehog 
signaling. Inflammatory cytokines such as IL-6 and IL-8 are noted to be crucial regulators of 
self-renewal capacity of CSCs, both in in-vitro and xenograft models224,227. These 
inflammatory cytokines induce the STAT3/NF-kB pathways in both tumor and stromal cells 
to further increase cytokine production (positive feedback cytokine loop), which drives CSC 
self-renewal mechanisms228. Serum levels of IL-6 and IL-8 in advanced breast cancer patients 
were positively correlated to metastatic occurrence and poor survival229,230. Further, studies 
have demonstrated that, cellular cytotoxicity induced by conventional chemotherapy leads to 
increased production of local IL-8 which may increase CSC population after chemotherapy, 
which can in turn result in cancer recurrences/metastasis224. Therefore, interfering this 
inflammatory cytokine loop in CSC niche provides a novel strategy to target CSC population. 
Antibodies/small molecule inhibitory compounds against IL-8 receptor CXCR1 have 
selectively depleted BSC population in in-vitro cell line models231. Similarly, anti-IL-6 
antibody shown to inhibit CSCs by suppressing JAK1/STAT3 pathway232. Monoclonal 
antibodies/inhibitors against IL-6 or its receptors have entered clinical trials for treating 
multiple myeloma233.  
1.8.2.4 Immunological approach to target CSCs 
In recent years, advances in immunotherapies for cancer therapeutics are promising and 
produced good clinical response with lower toxicities234. However, these therapies are currently 
focused to eradicate the bulk tumor, which might remise due to the presence of CSCs. 
Therefore, immunologic strategies specifically designed to target CSCs are probably required 
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to eradicate cancer recurrences. CSCs are phenotypically different from their differentiated 
bulk tumor cells and they are also heterogeneous due to their plasticity, which is regulated by 
genetic and epigenetic mechanisms. Therefore, it is crucial to find multiple novel antigens 
which are CSC specific in order to utilize immune based therapies. CSC markers such as 
ALDH1, CD44, CD133 etc., are currently used to isolate CSCs, however they are also potential 
targets for immune based therapies. One of the immunological approaches is to use dentritic 
cells (a professional antigen presenting cell) to produce tumor specific T cells. In one study, 
human CD8+ T cells were stimulated with ALDH peptide-pulsed autologous DCs (dentritic 
cells-antigen presenting cells) which significantly reduced ALDH+ tumor cells in vitro, 
preclinical patient derived xenograft growth and metastasis formation in immune deficient 
mice235. Another study, investigated DC primed with ALDH+ CSC in xenograft models, and 
showed that these vaccine can significantly reduce lung metastasis of melanoma cells 
compared to the vaccine (DC) primed with bulk tumor cells236. CSC primed DC vaccine 
combined with radiotherapy (RT) had significantly lower lung metastases compared to the RT 
treated group alone in mouse models237. It has been suggested that CSC primed DC vaccine 
can be used in an adjuvant setting to target microscopic residual cancer cells rather than 
targeting the bulk tumor as the ratio of CSCs are much lower compared to the entire tumor 
mass238. These data clearly highlight the importance of ALDH as a potential target for T cell 
based immunotherapy against CSCs.  Apart from ALDH, CD133 and HER2 receptors are also 
under investigation for priming different immune cells such as NK (Natural killer cells), T cells 
and DCs against CSCs239,240. Immunological approaches against CSCs are promising cancer 
therapeutics which can be combined with conventional therapies for preventing cancer 
recurrences.   
1.8.2.5 CSC metabolism inhibition 
Cellular metabolism is an important biological process for cell survival and proliferation. 
Different cells utilize different metabolic pathways such as oxidative phosphorylation 
(OXPHOS) or anaerobic glycolysis for their energy (ATP) production. Cancer cells tends to 
utilize anaerobic glycolysis to support their rapid proliferation rate even under normoxic 
conditions was first reported by Otto Warburg in 1920s241. This phenomenon is referred as 
“Warburg effect”. Similarly, several recent studies have demonstrated that embryonic and adult 
stem cells depend on glycolysis for their ATP production242. Even in the case of induced 
pluripotent stem cells (iPSCs), metabolic shift towards glycolysis has been reported243 and the 
expression of glycolytic genes was increased before the actual increase of stemness markers244. 
This suggests that metabolic reprogramming is crucial to acquire stemness phenotype. CSCs 
derived from breast cancers exhibit higher glycolytic metabolism245, while CSCs obtained from 
glioma where relying mainly on OXPHOS for their energy production246. This suggests that, 
CSCs can adapt to different oxidative stress situations depending on their microenvironment. 
Reduction oxidation (redox) homeostasis is another crucial factor for maintaining self-renewal 
and pluripotent capabilities193. Normal mammary epithelial stem cell have lower levels of ROS 
when compared to differentiated cells247, increase in ROS level can lead to lineage specific 
differentiation248. Similar to normal mammary stem cells, BSCs also exhibit lower ROS levels 
when compared with non-cancerous cells193. Warburg effect is also shown to be associated 
with mitochondrial activity and the redox levels in cancer cells249. Increased glycolysis and 
limited mitochondrial function may hinder mitochondrial depended ROS production, thereby 
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maintaining a CSC phenotype250. Warburg effect is often considered as a cellular response to 
hypoxic (lower oxygen) conditions occurring in tumor microenvironment, however in the case 
of BSCs, HIF1-α was found to be expressed in high levels even in normoxic conditions251. 
Lactate and pyruvate which are produced during glycolysis are found to be in higher levels in 
BSCs and they further induce hypoxia inducible genes independent of hypoxic conditions 
eventually leading to accumulation of H1F-1α even in normoxic conditions252. Alterations in 
metabolic pathways has been reported to induce different phenotypic changes in cancer cells, 
for instance silencing gluconeogenic enzyme fructose-1,6-biphosphate, which activates 
fermentative glycolysis resulting in a stemness phenotype250. CSCs isolated from different 
solid cancers exhibit higher glycolytic metabolism compared to their differentiated cancer 
cells253,254. Therefore, it is highly important to target CSC specific metabolism in order to 
eliminate them. A recent study demonstrates that, BSCs heavily rely on fermentative glucose 
metabolism and were found to be sensitive to 2-deoxyglucose (2-DG) treatment (a glycolysis 
inhibitor). Further research on CSC specific metabolomics can identify more CSC specific 
targets. 
1.8.2.6 CSC differentiation  
Another interesting way to target CSCs is to differentiate them, so that they become sensitive 
to the traditional therapies. This approach is very useful in hematological cancers such as acute 
promyelocytic leukemia, where treatment with retinoids substantially improved patient 
survival 255. In a recent study, all-trans-retinoic acid (ATRA) treatment in breast cancer cells 
inhibited ALDH1 activity and restored sensitivity to both chemotherapy and radiotherapy256. 
The possibility of differentiation therapy applied on CSCs is a promising approach to eradicate 
CSC population in tumor. In summary, it is widely accepted that a subpopulation of breast 
cancer cells possessing stem cell-like capabilities, with high plasticity, intrinsically able to 
escape from current clinical therapies plays a major role in tumor initiation and progression. It 
is vital to target BSCs along with the bulk tumor for improved breast cancer treatment response.  
 
Figure 3: Summary of various mechanisms to target cancer stem cells (CSCs) 
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1.8.3 Estrogen receptors and BSCs 
Estrogen is crucial for development of normal mammary tissue, however adult mammary stem 
cell population are known to be ERα-negative257. Residual cancer cells from neo-adjuvant 
endocrine therapy (aromatase inhibitor) treatment express mesenchymal and tumor initiating 
gene signatures191. This suggests that, hormone responsive breast cancers may contain 
hormone resistant BSCs. Isolated BSCs from breast cancer tissues and cell lines are reported 
to have reduced or no ERα expression257. Investigating the normal mouse and human breast 
development supports the cellular hierarchy pattern of ERα expression, where ERα negative 
stem cells give rise to ER positive luminal cells258. Although BSCs are ERα negative, estrogen 
stimulates BSCs mammosphere formation efficiency by induction of EGF, Notch receptor 
signaling pathways via paracrine regulation259. Earlier in this thesis, endocrine resistant 
mechanisms caused by other growth factor signaling where discussed, however the role of 
BSCs in endocrine resistance and the underlying mechanism is not well understood. One of the 
aims of my doctoral thesis is to study this mechanism and to elucidate the effect of tamoxifen 
on BSCs versus the adherent cells. In a recent study, a novel variant of ERα, called ERα-36 
found to be highly expressed in ER-positive breast progenitor cells and meditate antiestrogen 
resistance through induction of P13K/AKT in BSCs260.  
Apart from ERα, there is a second estrogen receptor called ERβ. These two ER subtypes are 
coded by different chromosomes. ERβ also binds with high affinity to estradiol-17β (E2) with 
its ligand binding domain (LBD), as there is a 58% homology in the protein sequences of the 
LBDs between the two Estrogen receptors261. Interestingly, they both share high homology 
(96% in human) in their DNA binding domains, which can bind to specific DNA sequences 
such as ERE (Estrogen Regulating Elements) and transcriptionally regulate the ER target 
genes. ERβ has been identified as the major form of ER expressed in the normal breast tissues 
using immunohistochemical (IHC) analyses, located in the luminal and myoepithelial cells 
of the healthy breast. ERβ is also present in various other cell types such as fibroblasts and 
lymphocytes in the tumor microenvironment262. ERβ expression has been studied in ERα-
positive and negative breast cancers. Around 58% of the cancers express both ERα and ERβ; 
while 14% express only ERα and 18% express only ERβ263-265. Studies determining the ERβ 
expression at the protein level using IHC techniques on the breast cancers were not always 
in consensus. In some studies, high levels of ERβ expression, irrespective of their ERα status 
correlated with a better response to hormonal therapy and a longer disease free survival266-
269.  In contrast, ERβ expression in ERα-negative breast cancers correlated with a poor 
prognostic phenotype such as increased proliferation has also been reported270,271. One 
possible reason for such variation in the expression studies of ERβ using IHC is due to the 
co-existence of multiple ERβ isoforms. Until now, the expression levels and the role of ERβ 
in BSCs are unknown. One of my paper in this thesis addresses this issue to evaluate the 
ERβ’s role in cancer stem cells and if we can potentially target them for endocrine treatment 
using ERβ specific antagonist.  
1.9 METASTATIC BREAST CANCER 
Breast cancer mortality is solely a consequence of the spread of primary cancers to distant sites 
known as metastasis272. Disseminated cancer cells from primary breast cancer can spread to 
multiple different organs and most preferably to bone, lung and liver272. Metastasis formation 
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is a multi-step process, where cancer cells acquire the ability to invade surrounding tissues, 
penetrate into lymphatic or blood vessels (a process referred as “Intravasation”), survive in 
circulatory system and eventually extravasate through the endothelium of a new distant organ, 
where the cancer cells attach and proliferate to form secondary cancer lesions273. 
Understanding the biological mechanisms behind the formation of metastasis are of utmost 
importance to prevent and eradicate metastatic disease. In this thesis, one of the most important 
mechanisms involved in the process of metastasis formation named “Epithelial to 
Mesenchymal transition- EMT” is discussed in detail.  
1.9.1 Epithelial to mesenchymal Transition (EMT) 
Epithelial to mesenchymal transition (EMT) process is involved in organ developmental 
process during embryogenesis274. As the name suggests, this process involves in changing the 
phenotype of an epithelial cell to a mesenchymal state and this process is exploited by cancer 
cell during cancer progression275. By EMT, cancer cells disrupt the cell adhesion molecules 
(CAMs)276, degrades neighboring extra cellular matrix (ECM)277 and the basement membrane, 
thereby increasing the motility and invasiveness of cancer cells278. Additionally, cells that have 
gone through EMT process acquire resistance to senescence and apoptosis274. Therefore, the 
EMT process is crucial during early stages of cancer cell dissemination from primary cancers.  
1.9.1.1 Regulators of EMT 
EMT processes can be induced by a plethora of signaling pathways such as transforming 
growth factor-β (TGF-β), Wnt, Notch, tumor necrosis factor-α (TNF-α/NF-kB) and 
P13K/AKT pathways279. Several transcription factors, including the snail/slug family, twist, 
EF1/ZEB1, SIP1/ZEB2, and E12/E47, respond to different micro environmental stimuli and 
function as master regulators of the EMT program279. In addition, snail family proteins 
collaborate with other transcription factors, such as twist and ZEB1, to orchestrate the EMT 
regulation280.  One of the main characteristics of EMT induction is loss of E-cadherin (a key 
cell-cell adhesion molecule) expression or activity 278. Twist, snail and slug represses E-
cadherin expression by directly regulating the E-box elements present in promoter region of 
this gene by recruiting co-factors and histone deacetylases281. Apart from the downregulation 
of E-cadherin, β-and γ-catenin expression, mesenchymal genes such as vimentin are 
upregulated. This results in alterations of morphological features (spindle-like) and increased 
migration in cells undergoing EMT282. High expression levels of snail have been observed in 
some invasive breast cancer283 and is linked to tumor grade, metastasis, recurrence and poor 
prognosis281,284,285.  
Apart from the signaling pathways, miRNAs are also a major player in regulating EMT 
program. When EMT program is induced, the expression of several miRNAs (miR-200 family 
and miR-205) are drastically reduced286. miRNA-200 family directly regulates the expression 
of ZEB1 and ZEB2 mRNA, thereby increasing the E-cadherin expression leading to epithelial 
phenotype286. Loss of miR-200 is reported in invasive breast cancer cell lines with 
mesenchymal phenotype. On the other hand, miR-10b expression is increased during EMT 
process, induced by twist and limiting the expression of HOXD10, which in turn facilitates the 
metastasis of breast cancer cells287. Other miRNAs such as miR-155, miR-29a and miR-21 are 
reported upregulated by TGFβ induced EMT. Also, their expression levels are higher in 
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mesenchymal like cell lines compared to epithelial like cells288,289. Overall, the differentially 
regulated miRNAs might be critical for EMT and cancer metastasis. Finally, EMT can also be 
regulated at genetic and epigenetic level.   For example, a gene mutation and hyper methylation 
at the promoter region of E-cadherin can inactivate this gene290. Molecular mechanism leading 
to promoter methylation of E-cadherin in breast cancer is not well understood.  
1.9.1.2 EMT and stemness 
Induction of EMT is closely associated with “stemness” in development process and 
carcinogenesis. During the gastrulation process, embryonic stem (ES) cells in the inner mass 
of the blastocyst have epithelial phenotype291 which ingresses to form the primary mesoderm292 
via induction of EMT process, illustrating the importance of EMT during the early 
differentiation process. The association of EMT and stemness also extends to carcinomas. 
Expression of snail and twist in mammary epithelial cells induce EMT, leading to a CD24-/44+ 
phenotype186, which is associated with breast cancer stem cells (as described before under 
breast cancer stem cell section). TGFβ signaling seems to be associated with EMT and CSC 
formation in cancer. Mammary CSCs express high amounts of TGFβ1 and TβRII than the more 
differentiated epithelial counterparts, and inhibiting TGFβ signaling in CSCs can re-establish 
the epithelial phenotype293. Apart from TGFβ signaling, Notch and Wnt Signaling also 
contributes in CSC generation in colon and pancreatic cancers, which is also known to induce 
EMT process294,295. Recently, a core EMT gene signature was identified and it correlated with 
claudin low and metaplastic breast cancer subtypes296.These evidences suggests that induction 
of EMT and the gain of CSC-like properties are closely linked, which may be crucial for 
metastasis. Changing phenotype from epithelial to mesenchymal state might be crucial for 
acquiring invasive abilities and survival benefits during systemic circulation for metastatic 
seeding.  
1.9.1.3 EMT and therapeutic resistance 
Considering the relationship between CSCs and EMT process, intrinsic drug resistance of 
CSCs can be partially explained by EMT mediated drug resistance. Indeed there are several 
reports suggesting that, EMT induction can cause therapeutic resistance. EGFR induced EMT 
is associated with increased tamoxifen resistance and increased invasiveness in the MCF7 cell 
line297. In another study, doxorubicin treatment increased the fraction of cells with EMT 
phenotype and they were resistant to vincristine and pacilitaxel298. Increased expression of twist 
was observed in highly invasive breast cancer cell lines, and the upregulated twist provided 
survival benefits and paclitaxel resistance299. Snail and slug over expression renders cellular 
resistance to apoptosis in MCF7 cells induced by the DNA damaging agent doxorubicin and 
increases invasive properties300. Basal-like tumors are often associated with poor clinical 
outcomes and it is interesting to note that, a subset of basal-like breast cancer cell lines were 
found to be clustered together with mesenchymal transcriptomic profile301. Further 
investigation on these specific cell lines demonstrated that  they were associated with an EMT 
phenotype, such as reduced expression of E-cadherin and increased expression of vimentin302. 
Underlying mechanisms between EMT process and drug resistance are not well understood. It 
is important to determine whether therapeutic drugs enrich for cells with EMT phenotype or 
these drugs induce EMT and in turn makes them therapy resistant. Identification of these 
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molecular mechanisms contributing the EMT and CSC induced drug resistance are crucial for 
the development of novel therapeutics to treat metastatic disease.  
1.9.1.4 EMT and Immunosuppression  
Immune surveillance is the host protection system against microbes and infections, and also 
for early cancer prevention. Cancer immune surveillance is critical for inhibiting tumorigenesis 
and to maintain cellular homeostasis. Unfortunately cancer cells evade immune surveillance 
by suppressing immune cells in the host303. It has been reported that cancer cells undergoing 
EMT acquire immune suppressive properties275, suggesting that cancer cells can utilize the 
EMT process for survival during cancer initiation and cancer cell dissemination to escape 
immune system. It has been reported that snail-induced EMT increase metastasis through 
induction of immunosuppressive cytokines and regulatory T-cells (Treg), as well as impairing 
the dendritic cells (DC) and cytotoxic T-cell functions304. Further, snail knock-down 
significantly reduces tumor growth and metastasis formation by increasing tumor-infiltrating 
lymphocytes and systemic immune responses304. Another signaling pathway regulating the 
EMT process is Wnt/β-catenin, which is also known to generate regulatory DCs and increase 
regulatory T-cell survival, thereby compromising the cancer immune surveillance305. 
Therefore, therapies targeting EMT process could be both anti-metastatic and anti-
immunosuppressive in cancer patients274.  
1.9.2 Mesenchymal to epithelial Transition (MET) 
Substantial amount of research is currently focused on identifying the biological processes 
involved in metastasis formation such as, EMT. However less is known regarding, how 
disseminated tumor cells are colonizing distant sites. Mesenchymal to epithelial transition 
(MET), opposite of EMT process has been proposed as the main mechanism for the successful 
seeding and outgrowth of metastatic lesions at distant sites such as bone, lung, liver, brain etc., 
Intravasated cancer cells from primary tumor are capable of surviving in systematic circulation, 
this may be due to their EMT phenotype274. Extravasation of disseminated cancer cells (also 
referred as circulating tumor cells – CTCs) to secondary distant site requires recognition and 
adhesion to vascular endothelial cells and invade distant organ by matrix degradation273. All 
these processes demands a highly plastic and motile phenotype similar to “mesenchymal like” 
cells306. MET process is a relatively under investigated mechanism which might be crucial for 
colonization of cancer cells in distant organs307.  
1.9.2.1 MET during metastasis formation 
Importance of EMT process in early stages of metastasis were discussed earlier, emphasizing 
that disseminated cancer cells from primary tumors are in “mesenchymal-like” phenotype. 
However distant metastatic lesions have been reported as of “epithelial-like” breast cancer 
phenotype in the ectopic tissues308,309. Researchers have reported that E-cadherin expression 
(loss of E-cadherin is the hallmark for EMT process) is equal or higher in distant metastases 
when compared with their respective primary cancers308. In two other studies, E-cadherin 
expression was observed to be higher in metastatic lesions, originating from E-cadherin- low 
or negative and poorly differentiated primary cancers310,311. More than 50% of liver, brain and 
lung metastases express high levels of E-cadherin compared to the infiltrating primary breast 
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ductal carcinoma309. Using In-vitro xenograft mice models, injection of invasive, metastatic 
mesenchymal like MDA-MB231 breast cancer cells in mice produced spontaneous lung 
metastases  expressing higher E-cadherin than the parental tumor cells310. Mice xenograft 
experiments using MDA-MB-468 breast cancer cells revealed a gradual transition of invasive 
cancer cells with mesenchymal phenotype to epithelial phenotype in lymph vasculature312. 
These data suggests that, MET process can be a plausible explanation for re-expression of E-
cadherin and importance of MET at metastatic sites. Micro environmental factors in the distant 
organs also contribute to the re expression of E-cadherin and the subsequent MET process. In 
another study, E-cadherin negative MDA-MB231 cells re-gained E-cadherin expression when 
co-cultured with hepatocytes in a metastatic xenograft model, indicating the significance of 
micro environmental ques on the MET process313. 
1.9.2.2 MET is crucial for active cell proliferation 
Several reports have demonstrated that invading cancer cells undergoing EMT proliferate less 
compared to their non-migratory primary cancer cells314,315. Invasive front of primary 
colorectal adenocarcinoma are reported to have low Ki-67 expression, while the center of the 
tumor expresses high Ki-67314. They observed low E-cadherin expression and nuclear localized 
β-catenin in these Ki-67 negative cells. Another study reported higher expression of cell cycle 
inhibitor, p16INK4A (inhibitor of kinase 4) in invasive front of colorectal cancers compared to 
the tumor center, suggesting the inverse correlation of EMT and proliferation314. EMT induced 
reduction in cell proliferation is believed to be caused by EMT regulators such as β-catenin, 
snail and ZEBs. For instance, over expression of snail and ZEB2 induced EMT and demised 
cyclin D1 in kidney (MDCK) and epidermoid carcinoma cells316. In colon cancer cells, ZEB1 
expressed in invasive fronts and is associated with lower proliferative markers317. Therefore, 
for a successful outgrowth of cancer cells to colonize the secondary site, it seems the transition 
from mesenchymal phenotype to epithelial phenotype is required to provide growth 
advantages.  
Factors secreted by active stromal compartment such as bone marrow-derived myeloid 
progenitor cells, present in the secondary site microenvironment induces MET process on 
MDA-MB231 cells and provide a favorable pre-metastatic niche318. This factor (chondroitin 
sulphate proteoglycan versican) increased the cell proliferation by suppressing snail expression 
in MDA-MB231 cells thereby aid in formation of metastases in a xenograft model. In a recent 
study, Lawson et al, demonstrated that metastatic cells exhibit EMT and stemness 
characteristics in low-metastatic burden sites compared to high-metastatic burden tumors in 
PDX models, using FACS (Fluorescent activated cell sorting) based single cell analysis319. 
High metastatic burden tumors were similar to primary tumor, which were more heterogeneous 
and expressed high levels of luminal differentiated genes with increased proliferation319. 
Therefore, initiation of metastatic process by EMT and stem-cell like cells followed by MET 
during re-colonization of cancer cells at the secondary site is crucial for establishing advanced 
metastatic disease. Although this alteration of EMT to MET are demonstrated using cell lines 
and xenograft models, no direct evidences of MET in actual human derived metastatic lesions 
compared to their respective parental primary cancers are studied until now. Furthermore, it is 
unclear whether this MET in metastatic lesions are stable phenotype or these cells can further 
undergo another round of EMT process to seed successive metastases. In summary tumor 
progression can be conceived as a highly dynamic process with change of different phenotypes 
 26 
rather than a stable process where cancer cell progress with higher and higher degree of 
dedifferentiation and proliferation. 
 
Figure 4: Schematic representation of biological processes involved during metastasis. 
Modified from Wai Leong Tam and Robert A Weinberg (2013)320. Reprinted with permission 
from Macmillan Publishers Ltd: Nature Medicine, copyright (2013) 
1.10 MODES OF BREAST CANCER METASTASIS AND SEEDING PATTERNS 
In breast cancer biology, it is not clear how distant metastases arise from primary cancer. Much 
uncertainty still persist on when cancer cells dissemination occur, either at early or at late stages 
of cancer development, and whether multiple distant metastases arise directly from primary 
tumors (in parallel fashion) or they give rise to each other (linear or cascading fashion) remains 
to be answered. Genetic alterations during cancer progression acts as forensic evidence, to 
study the phylogenetic relationships of metastases and primary cancer. Most genetic alterations 
may or may not be crucial for actual metastases formation process, however they can provide 
valuable information regarding past dissemination events and their origin. Four models of 
metastatic progression has been proposed; linear and metastatic cascade progression, parallel 
progression, tumor self-seeding and dormancy321.  
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1.10.1 Linear progression model 
“Linear progression model” is one of the traditional models suggested for metastatic 
progression in cancer. This models assumes that only genetically advanced cells can leave the 
primary tumor and successfully colonize a distant site. Multiple clonal expansions during 
primary cancer development leads to cancer cells with disseminating phenotype in a stepwise 
manner322. Therefore, in this model metastasis is assumed to occur shortly after a tumor 
becomes clinically detected, that is during later stages of primary cancer development. Further 
linear progression model predicts a smaller evolutionary distance between primary and 
metastatic lesions thereby suggesting that primary tumors can be a good surrogate for the 
molecular phenotypes of metastases.  However, there is another model similar to linear 
progression called “metastatic cascades”, during later stages of cancer progression323. Highly 
vascularized central organs such as lung and liver are reported to give rise to successive 
metastases in a cascading manner also referred as “shower of metastases”324. Metastatic 
cascade model predicts aggressive and high growth rate of metastases323. According to this 
model once, a distant organ is colonized with a metastatic cancer cell population, they in turn 
give rise to successive metastases which are more-closely related to each other than to the 
primary tumor.  
1.10.2 Parallel progression model 
Parallel progression model assumes that the cancer dissemination occurs early in the tumor 
progression325 and that primary cancer and distant metastases evolve independently323. Parallel 
progression is opposite to linear progression model as it suggests that disseminated cancer cell 
doesn’t have to be in a genetically advanced state (high mutational load) and few mutations 
can be enough to trigger the dissemination process. According to this model, distant metastases 
can evolve separately and extensively adapt itself to the local microenvironment, thereby 
substantial genetic diversity between metastases and its primary tumors, as well as between 
metastases at different anatomical sites is observed. Under this model, using primary cancer 
characteristics for treating metastatic disease becomes invalid. 
1.10.3 Tumor self-seeding / bi-directional seeding model 
“Tumor self-seeding” model is a recently coined hypothesis which proposes that cancer cell 
dissemination can be bidirectional, with dynamic cell exchange between synchronous tumor 
lesions326, while both linear and parallel models regard metastasis progression as unidirectional 
process that begins from primary tumor and ends in metastases. Primary cancers are proposed 
to shed cancer cells into systemic circulation, where highly selective circulating tumor cells 
(CTCs) can return to the same primary tumor to drive progression. Similarly, metastases at a 
distant site can shed cancer cells into the systemic blood circulation and then back to the 
primary tumor. This process can hinder the genomic evidences of independent tumor evolution 
at different anatomical sites as in the case of parallel progression.  
1.10.4 Dormancy model 
Dormant cancer cells may be one of the reasons for really late recurrences that is, after more 
than 10 years of disease free survival327. Dormancy model proposes that disseminated cancer 
cells can be dormant for many years by being in a “senescence-like” state at a potential distant 
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site or colonized tumor mass with very low proliferation (“tumor mass dormancy”) at distant 
sites. Since dormant cells do not divide, they do not accumulate mutations, therefore genomic 
evolutionary analyses doesn’t reveal whether a metastatic lesions arose at late stages of cancer 
progression or they underwent a period of dormancy at the distant site. Until now, tumor mass 
dormancy cannot be demonstrated in human cancers, as it is difficult to find a tumor mass at 
distant metastasis which is not dividing, metachronous, and it should ideally be genetically 
identical or very similar to the primary cancer without any specific accumulation of mutations.  
Recently, patterns of metastatic spread in prostate cancer was revealed by sequencing multiple 
metastatic lesions along with their respective primary tumors in ten patients. This study 
demonstrated that prostate cancer cells can spread in both monoclonal or in a polyclonal fashion 
and metastasis can seed successive metastasis (metastatic cascading)328.  Metastatic cascading 
model was also evident in pancreas329 and renal cancer330. However it is still unknown whether 
metastases can give rise to successive metastasis in breast cancer. In breast cancer studies are 
limited to multi region DNA sequencing of primary breast cancers that revealed high 
intratumoral heterogeneity and subclonal evolution during breast cancer progression83. In 
addition, DNA sequencing have been performed in the primary tumor and one metastasis of a 
single patient78-80. In order to investigate progression models, more than one distant metastatic 
lesion and primary tumor must be sequenced, and acquiring such multiple metastatic lesions 
from the same individual is difficult. In a recent study, multi colored lineage tracing xenograft 
experiments demonstrated that breast cancer metastases arise from multiple subclones present 
in the primary cancer331. More extended validation of this polyclonal seeding phenomenon has 
to be validated in clinical samples.  
1.10.5 Involvement of axillary lymph node metastasis in distant metastatic 
spread 
It is still unclear if distant metastases are seeded via the lymphatic or haematogenous route in 
breast cancer. Local regional and distant lymph nodes are the most common sites of metastatic 
engagement and are two-fold more frequent than lesions in the second most common site of 
metastasis i.e., liver332. Although positive axillary lymph nodal status has high negative 
prognostic value in breast cancer333, its role in seeding distant metastasis has not been validated 
in clinical studies. Due to its negative prognostic value, it has been assumed that axillary lymph 
node metastases may be the precursor of distant metastatic lesions.  This motivated extensive 
surgical and radiotherapy interventions to eradicate local regional disease334. However some 
researchers question the benefit of such interventions335,336and even argued that lymphatic 
lesions are unlikely to seed distant metastases337. One study also reported that positive axillary 
lymph nodes do not metastasize338. Evident role of ipsilateral axillary lymph node metastasis 
in seeding distant metastasis is not yet proven. Inferring this, will provide more insights about 
the routes of metastatic spreading and the importance of axillary lymph node metastasis during 
cancer progression. One approach to investigate this issue would be to sequence the axillary 
lymph node metastases along with the subsequent distant metastases and primary tumor, and 
performing phylogenetic analyses to understand their genetic relationship between them can 
be the way forward to answer this question. 
 
  29 
 
Figure 5: Schematic representation of different cancer progression models. a) Linear 
progression model b) parallel progression model c) axillary lymph node seeding distant 
metastasis 
1.11 ALTERED CANCER BIOLOGY IN METASTASIS 
Primary breast cancers are curable to about 50% 339 with present treatment regimes. However, 
distant metastasis are rarely curable with the same treatment strategies. The difference in the 
treatment response between primary cancer and distant relapses are attributed to an ongoing 
evolution of cancer cells leading to treatment resistant cancer cell populations84. In our group, 
we have previously shown that clinically used markers such as ER, PR and HER2 are altered 
in recurrent breast cancers when compared to their respective primary cancer. ER, PR and 
HER2 were altered in 33.6%, 32.0% and 15.7% of patients respectively when assessed with 
multiple consecutive relapses to their primary cancers164.  Further, patients with ER-positive 
primary tumors that changed to ER-negative in metastatic lesions had a significant increased 
risk (48%) of death164. From this study, it is evident that breast cancer evolves during cancer 
progression leading to change in clinical biomarker expression and in turn affecting the 
outcome.  Alterations in therapy predictive biomarkers in metastasis also lead to change in 
clinical management in 1 out of 6 to 7 patients340,341. Although these studies are based on IHC 
based analysis, alterations of molecular intrinsic subtype based on PAM50 analysis during 
cancer progression using matched primary-metastasis will provide more additional validation 
of the existing data.   
Alterations in the tumor characteristics during cancer progression can be attributed to one or 
more following reasons; First, primary breast cancer are known to exhibit high intra tumor 
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heterogeneity with varying metastatic capabilities273. Second, inherent host and cancer biology 
can induce clonal expansion of specific subclones in primary tumor, leading to the spread of 
these sub populations with distinct characteristics to colonize distant sites thereby affecting 
patient’s survival outcomes342. Third, biological process such as EMT-MET during metastasis, 
and microenvironment at systemic circulation and at distant organs has the potential to enrich 
certain subclones273. Finally, adjuvant therapies can also induce enrichment of treatment 
resistant clones which can metastasize with different characteristics from those of primary 
cancers343.   
Treatment in the metastatic setting is often based on the characteristics of the primary tumor. 
However, it is evident that standard biomarkers can change during cancer progression. 
Therefore, investigating the tumor characteristics of relapses are crucial to improve the patient 
survival. Many breast cancer clinical management consortiums such as Conference on 
Advanced Breast Cancer (ABC1), American Society of Clinical Oncology (ASCO), European 
Society for Medical Oncology (ESMO) and Swedish Breast Cancer Group (SweBCG) now 
recommends to examine the relapse tumor characteristics with regards to the expression of ER, 
PR and HER2344-346. Before we begin to personalize the clinical management in a metastatic 
setting, we must validate the relapse tumor characteristics with patient survival. For this 
purpose a study from our group previously reported that intrinsic molecular subtype of relapses 
significantly influences post-relapse survival based on relapse tumors from 111 patients, 
suggesting that molecular characterization of distant lesions does provide prognostic and 
clinically relevant information347. Moreover, this study also identifies key signaling pathways 
such as high AKT-MTOR, RAS and BETA-C are significantly associated with poor post-
relapse survival. Patients with poor-post relapse survival were also found to express high basal-
like, cell cycle and mesenchymal related genes, and express low amounts of luminal and 
apoptotic pathway genes347.  
Analyzing multiple metastatic lesions for therapy management is difficult as it requires 
complicated invasive procedures and can be confounded by intra-tumor heterogeneity330, 
therefore noninvasive liquid biopsies would be ideal to monitor the tumor progression. 
Recently it has been shown that, blood in systemic circulation contains DNA derived from 
different metastatic lesions referred as “circulating tumor DNA” (ctDNA) and tumor cells 
which are shed by metastatic tumors known as “circulating tumor cells” (CTC)348. Latest 
advancement in the field of genomics has made it possible to use ctDNA for determining 
genomic alterations such as rearrangements349, amplifications350 and to identify therapy 
induced resistant mutations351. Investigating them would provide a more comprehensive 
overview of the status of genomic alterations across different metastatic lesions than analyzing 
a single metastatic lesion350. Several researchers have been able to confirm that mutations 
present in ctDNA are concordant with that of the matched primary tumor351,352. Comparative 
genomic analysis on plasma derived ctDNA and synchronous metastatic lesions in two patients 
revealed a good overall correlation between them, but also reported an increase of certain 
mutations allele frequencies350 as it represents the bulk of tumor burden from different 
metastatic sites, which can be an advantage for such a method. Currently less is known 
regarding the mechanism of DNA release from the tumor cells. It is highly important to know 
what type of cancer cells release DNA; whether it is highly proliferative or dying cancer cells. 
If it is dying cancer cells, then it is not as clinical important as it has limited potential to target 
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cancer with that acquired information from ctDNA. On the other hand, CTCs are intact cancer 
cells from which functional studies can be performed to reveal novel therapeutic targets and 
identify drug resistance mechanisms during cancer progression. Thus, CTCs are also crucial to 
investigate which can provide additional information regarding the metastatic disease, 
complementing ctDNA. Intra and Inter metastatic tumor heterogeneity might complicate the 
interpretation of the data, but in principle ultra-deep sequencing of ctDNA can provide 
additional information on tumor heterogeneity and clonal evolution at distant metastatic lesions 
as well353, although this is yet to be proven. Further, sensitivity, specificity, predictive and 
prognostic value of ctDNA in clinical setting has to be evaluated. If clinically proven, ctDNA 
has the potential to strengthen the idea of personalized medicine in clinic for monitoring and 
managing advanced breast cancer disease.
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2 AIMS OF THE THESIS 
The aim of the thesis is divided in to two parts; first we optimized a working protocol to isolate 
breast cancer stem cells from breast cancer patients, after which we investigated estrogen 
signaling and anti-estrogen therapy resistance in breast cancer stem cells (BSCs). In the second 
part, we investigated the extent of genomic alterations in metastatic lesions with respect to their 
corresponding primary tumors and the patterns of metastatic spread in humans.  
The individual aims of each paper included in this thesis are described below: 
Paper I: The aim of this study was to optimize a methodology called “superficial scraping 
from tumor surface” to biobank small breast tumors for future research purposes, without 
compromising routine histopathological assessments. We further investigated if this method 
could be used to isolate and propagate breast cancer stem cells (BSCs) from tumors. 
Paper II: In this study, we aimed to investigate the expression and the function of second 
estrogen receptor; ERβ in BSCs, which can be a potential target for endocrine therapy against 
BSCs. 
Paper III: The aim of this paper was to understand the mechanism of tamoxifen resistance in 
both cell line and patient derived BSCs. 
Paper IV: The aim of this study was to examine the patterns of metastatic breast cancer spread 
and the role of ipsilateral axillary lymph node metastasis in seeding distant metastasis, using 
exome sequencing data from matched primary breast cancer and metastatic lesions.  
Paper V: In this study, we aimed to investigate to what extent transcriptomic profiling of 
therapy predictive biomarkers and prediction of molecular subtypes are displaying intra-tumor 
heterogeneity in breast cancers. 
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3 MATERIALS AND METHODS 
3.1 PATIENT SAMPLES AND ETHICS 
All the fresh breast cancer samples were obtained from Karolinska University Hospital, 
according to the standardized surgical procedures. For the first three papers (Paper I, II and III) 
included in this thesis, utilized the “superficial scraping technique” to isolate cancer stem cells 
from fresh tumor samples. Detailed methodology of superficial scraping technique is discussed 
in Paper I. Paper II and Paper III included around 88 and 23 fresh cancer samples patients 
respectively. Normal breast samples were acquired from reduction mammoplasties surgeries 
at Capio St Göran’s Hospital, Stockholm, Sweden. For Paper IV, we assembled a retrospective 
cohort of 20 patients with metastatic disease. These patients were identified through the IT-
support system using the digitalized patient medical records. The search term was “metastatic 
adenocarcinoma” and the years included were 2000 through 2011 (N =3823). We retrieved the 
FFPE tumor blocks from primary tumors, local recurrences, ipsilateral axillary metastases and 
distant metastases for these patients. We isolated RNA and DNA, from all the FFPE tissue 
blocks, to perform gene expression and whole exome sequencing. Tissue microarray (TMA) 
blocks were made to analysis standard breast cancer biomarkers using IHC. For the last Paper 
(Paper V), fresh tissue biopsies were isolated from 12 breast cancer patients. From each one of 
these patients at least two spatially separated tumor pieces were collected and snap-frozen. In 
total, 43 pieces were collected (2-6 pieces per tumor). For all studies, permits were acquired 
from the Stockholm medical biobank and the experimental procedures were approved by the 
regional ethics review board (Etikprövningsnämnden) in Stockholm, Sweden. All the patient 
IDs were coded for study purposes and anonymised for publications. 
3.2 CANCER STEM CELL ISOLATION 
Cancer stem cell isolation from primary breast cancer samples and cell lines is a crucial 
methodology deployed in most of my papers. We used selective medium containing necessary 
growth factors such as EGF, FGF and insulin, and lacks serum. This media promotes cells to 
grow in ultra-low attachment conditions and aids self-renewal and a stemness phenotype. 
Detailed methodology of cancer stem isolation is described in Paper I. We have characterized 
the cancer stem cells isolated using this method using FACS and immunofluorescence (IF) 
staining techniques.  FACS identified around 30% of mammospheres as ALDH1high and 40-
50% of mammospheres as CD44+/CD24- (Paper I, Figure 3c). IF staining illustrated that 
cultured mammospheres were CD44+/CD24-, ALDH1high and EpCAM+.  
3.3 MOLECULAR TECHNIQUES 
In this thesis, a number of different molecular techniques have been used. Some of them are 
stated below. Effects of different compounds on the growth of cancer stem cells are measured 
using mammosphere formation and proliferation assays. Next, in order to study the protein of 
interest in mammospheres, immunofluorescence (IF) technique was used after cytospin 
technique. This technique requires very low amount of cells, thereby it is perfect for staining 
valuable patient materials. Western blot analysis were performed to study the panel of proteins 
involved in a signaling pathway (e.g., mTOR pathway), but it requires large amount of sample, 
therefore, cell line derived spheres were mostly used for western blot analysis. For adherent 
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cancer cell lines, WST-1 assay was used to measure the cell viability after treatment with drug 
of interest.  Quantitative real time PCR is also a major technique, used throughout my thesis to 
measure mRNA levels at different experimental conditions. Detailed methods are described in 
the “materials and methods” section of each paper. 
3.4 BIOINFORMATICS 
A wide range of bioinformatics were performed in this thesis. Analysis and interpretation of 
the raw data acquired from different experiments was performed by myself, with the support 
of bioinformaticians in our group. In paper II and paper III, microarray based gene set 
enrichment analysis (GSEA) were performed to identify pathways, which are significantly 
affected during specific drug treatment in cell line and patient derived CSCs. In paper IV, whole 
exome sequencing was performed on 99 FFPE tumor samples from 20 breast cancer patients, 
to investigate cancer progression. We investigated the evolutionary history of cancer cells 
across different tumor sites of the same individual by a method called “Dollo parsimony”. 
Further, subclonal analysis was performed using a method called “Pyclone”. Our collaborators 
at the University of Helsinki, provided bioinformatics support on mutational signature analysis 
during breast cancer progression. In paper V, RNA sequencing and microarray analysis were 
performed on multiple regions of same primary tumor. Intrinsic molecular subtypes were 
determined based on the gene expression profile to demonstrate the transcriptional intra tumor 
heterogeneity. Detailed description of the methods are provided in the “materials and methods” 
section of each paper. 
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4 RESULTS AND DISCUSSION 
4.1 PAPER I 
Superficial scrapings from breast tumors is a source for biobanking and research 
purposes. 
Apart from the routine pathological assessments many cancer hospitals store the valuable 
tumor specimens for future research projects or for future clinical investigation354. Currently 
there are two ways of bio banking tumor samples; 1. Resected breast cancer tissues are 
preserved in formalin fixed paraffin embedded blocks (FFPE). These blocks are ideal for 
investigating predictive IHC markers and for any protein of interests in future. DNA isolated 
from sections of FFPE blocks are now used for whole genome sequencing analysis355. RNA 
and protein isolation from FFPE is still not well optimized. 2. Surgically removed breast cancer 
tissue pieces are snap frozen and stored in a low-temperature freezers. This storage method is 
good for preserving DNA, RNA and protein for later research purposes356,357. For downstream 
molecular analysis such as DNA/RNA sequencing, fresh frozen tissues are preferred over 
FFPE blocks. But there are problems with biobanking small breast tumors. With the latest 
advancement in mammography, increased number of patients are surgically treated at early 
stage with very small tumors. Moreover, increased usage of neo-adjuvant therapies leads to 
reduced tumor sizes at the time of surgery. Tumors less than 10 mm are currently difficult to 
biobank because all the resected tissue is needed for routine histopathological analysis. This 
might lead to storage of increased number of large tumors and reduced number of small tumor, 
thereby creating an inherent bias for later research activities. Therefore, there is a need for an 
efficient and elegant method to biobank small breast tissues for research purposes. 
In this study we reported a simple and robust technique called “superficial scraping method” 
for isolating epithelial breast cancer cells. First, we investigated the tumor cell percentage 
present in the smears after scraping the tumor surface. Cytological assessment of the smears 
was investigated by a board-certified cytologist. Microscopic evaluation of smears from eight 
patients revealed that all eight patients had more than 95% cancer cells in their smears, while 
corresponding hematoxylin-eosin stained tissue sections contained 75-80% cancer cells. 
One of the most important part of the study was to generate CSCs by the scraping method. It 
has been previously reported that CSCs can be isolated by culturing breast cancer cells in vitro 
in ultra-low attachment plates by letting them form multicellular spheres180,358. Normal 
adherent cancer cells tend to undergo apoptosis under these conditions leading to enrichment 
of cancer cells with CSC phenotype in the form of mammospheres180,358. Tumor cells are 
isolated by scraping three-ten times by scalpels on the surface of the tumor and then directly 
transferred into conditional stem cell media (serum free) and cultured in ultra-low attachment 
plates. After 3 days of culturing, tumor cells tended to form clumps that are enzymatically 
dissociated into single cells and continued to be culture in conditional stem cell media for 5 
more days, leading to mammosphere formation. We could able to produce mammospheres 
from all four major molecular subtypes of breast cancer. In addition, we could also able to 
propagate the cultures for three more generations. Immunocytochemistry revealed the presence 
of CSC markers CD44+, CD24-, ALDH1+ and PKH26+ in patient derived mammospheres. 
Further, using FACS, we determined that around 30% of cells in mammospheres were 
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ALDH1+ and 40-50% of cells were CD44+/CD24-. These experiments suggested that the 
mammospheres isolated using scraping method are phenotypically similar to CSCs. Adherent 
patient derived cancer cells could also be cultured by dedifferentiating mammospheres in 
serum rich medium.  
Next, we analyzed the DNA/RNA isolated from fresh frozen scrapping material and compared 
it with the fresh frozen bulk tumor. Data revealed that DNA/RNA isolated from both materials 
are of similar quality and meet the quality assurance standards for next generation sequencing 
(NGS). Further, RNA isolated from scrapings were of good quality for downstream RTPCR 
analyses. We also showed that DNA from tumor scrapings retained the methylation status of 
genes, after observing higher ERα promoter methylation in an ERα negative patient.  
In summary, we show that superficial scraping technique can be used for biobanking small 
breast tumors and could potentially increase the number of breast cancers biobanked at our 
hospitals. Approximately 60% of all breast cancers operated at Karolinska University Hospital 
are currently stored in the form of fresh frozen tissue. By including scraping material we can 
also include the small tumors in the biobank.  Microarray analysis and next generation 
sequencing are at the verge of entering breast cancer clinics and it is highly important to find 
novel methods to include majority of the operated breast cancers for this purpose. In this study, 
we show that the quality of DNA and RNA isolated from scrapings are good for NGS and gene 
expression studies respectively. Further, we demonstrate that CSCs can be isolated from these 
scraping materials and clinicians can provide this valuable clinical samples to researchers 
without hampering their regular pathological assessments. Currently CSCs are isolated from 
fresh biopsies which are seldom available to researchers. We have used this method to isolate 
CSCs from patients for two of the following studies included in this thesis.  
4.2 PAPER II  
Estrogen receptor β as a therapeutic target in breast cancer stem cells. 
A subpopulation of breast cancer cells with stem cell phenotype referred as “cancer stem cells” 
(CSCs) are highly tumorigenic and possess tumor initiating capabilities179. Interestingly, a few 
hundreds of these cells are enough to reestablish tumors in mouse xenograft models177,179. 
Although breast cancer stem cells (BSCs) are ERα negative, these cells can be expanded by 
incubation with estradiol359. This motivated us to investigate the second estrogen receptor; ERβ 
in BSCs.  
Firstly, dual immunohistochemical staining of ERβ and CD44 in a cohort of 187 patients 
revealed that ERβ was enriched within the CD44+ cell population without any specific 
correlation to molecular subtype. Mammospheres isolated from patients where characterized 
for phenotypic stem cell markers. Similar to previous reports we found that CSCs are ERα 
negative, however they also expressed ERβ. Similar to BSCs, mammary stem cells (MSCs) 
were also ERβ-positive and ERα-negative. Also, cell-line derived mammospheres expressed 
5-11 times higher levels of ERβ and other stem cell genes such as SOX2, NANOG and OCT4 
when compared against adherent counterparts. These results indicate that ERβ is 
predominantly expressed in MSCs and BSCs. 
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Next, to investigate if ERβ plays any role in maintaining the stem cell phenotype, shRNA-
mediated knock-down of ERβ (MCF7 and MDA-MB231) was performed. ERβ knock down 
reduced the mammospheres forming efficiency by 41% and 27% in MCF7 and MDA-MB231 
cell lines respectively. This phenomenon was also verified in patient derived CSCs. In contrast, 
overexpression of exogenous ERβ increased the sphere-forming capacity in successive 
generations of mammospheres. Further, forced differentiation of patient-derived spheres also 
reduced ERβ expression and ALDH1 expression indicating a tight connection between ERβ 
and the stem cell phenotype.  
To investigate if ERβ can affect the proliferation of CSCs, the ERβ-selective agonist 
Diarylproprionitrile (DPN-70-fold selectivity over ERα) was used. DPN significantly 
increased the number of mammospheres from cell-lines compared to the untreated controls. 
This finding was also confirmed in patient-derived primary tumor cells. Further, DPN 
treatment of MCF7 spheres induced embryonic stem cell gene expression and induction of the 
ER-target genes PR and PS2, which are biomarkers for functional ER-signalling. To further 
explore ERβ mechanism of action on CSCs, we performed whole-transcriptome analysis of 
mammospheres. Treatment with DPN revealed significant enrichment of “Glycolysis 
metabolism pathway”. Hence, L-lactate assay was performed on after DPN treatment to 
validate the effects on the glycolytic process. DPN treatment of both cell line and patient 
derived mammospheres significantly stimulated L-lactate secretion and the ERβ antagonist 4-
[2-Phenyl-5,7bis(trifluoromethyl) pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) neutralized 
the stimulation by DPN, confirming the specificity of DPN. However, DPN failed to induce L-
lactate secretion after ERβ knockdown in MCF7 spheres. Additionally, DPN impaired the 
oxygen consumption rate of mammospheres, thereby shifting the cells towards glycolysis.  
Using in-vivo xenograft models from MCF7 and MDA-MB231 cells, we confirmed that ERβ 
induces tumor growth and can be targeted by PHTPP. We also found similar effects in two 
patient-derived PDX models (triple negative breast cancers) indicating that targeting ERβ is a 
potential therapeutic strategy for triple negative cancers. For luminal breast cancer, we sought 
to investigate whether a combination of tamoxifen and ERβ-modulator would be more efficient 
to block tumor growth as a consequence of ERβ expression in CSCs. Combining tamoxifen 
with PHTPP caused a gradual decrease of tumor size with increasing concentration of PHTPP 
in MCF7 derived xenograft, indicating that PHTPP in combination with tamoxifen can 
synergistically reduce tumor growth. 
This study identifies the predominant ERβ expression in BSCs and the role of ERβ in 
maintaining stem cell phenotype.  ERβ stimulation increase mammosphere proliferation by 
regulating glycolytic metabolism which is in turn is crucial for the cancer stem cell 
phenotype360. We propose a novel concept of breast cancer stem cells which are estrogen 
sensitive through the expression of ERβ, and a novel target for endocrine therapy for targeting 
CSCs. 
4.3 PAPER III 
mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells 
Tamoxifen is a selective estrogen receptor modulator (SERM) and has remained as the major 
focus in endocrine therapy of ERα-positive breast cancer during the last few decades22. 
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Tamoxifen is the first line therapy for hormone receptor positive breast cancers for 
premenopausal women and even suggested for many post-menopausal women because of its 
side effects. However, 30-40% of patients with metastatic disease initiated from hormone 
responsive primary tumors do not respond to tamoxifen2. Many mechanisms have been 
proposed for this effect such as lost ERα expression164, acquaintance of ERα mutation during 
endocrine therapy165, cross reactivity with other growth factor signalling361, presence of the 
second estrogen receptor (ERβ)362 and deregulated PI3K/AKT/mTOR signalling363 can affect 
the effectiveness of tamoxifen leading to tamoxifen resistance. In previous work, we observed 
that tamoxifen doesn’t affect the proliferation of patient derived mammospheres. This 
motivated us to further investigate the tamoxifen resistant behaviour of breast cancer stem cells, 
which might provide more insights on CSC induced tamoxifen resistance.  
First, we characterised the mammospheres derived from patients as described before. 
Mammospheres showed high expression of ALDH1, CD44, cytokeratin and EpCAM, and low 
expression of CD24. CSCs were shown to express lower levels of ERα257. To study the effect 
of tamoxifen on mammosphere forming capacity, patient derived mammospheres (n=5) were 
dissociated and treated with 4-OHT (4-hydroxy tamoxifen - a metabolite of the antiestrogen, 
tamoxifen, in humans and other mammals) 100 nM for 12 days. Tamoxifen did not affect the 
viability and mammosphere forming ability of CSCs. Additionally, we tested the effect of 
tamoxifen on three different ERα positive adherent cell lines (MCF-7, T47D and ZR-75-1) and 
corresponding mammospheres. Mammospheres were treated with varying concentrations of 
tamoxifen (100nm-10µM) for 5 days. Similar to patient derived spheres, cell viability of cell 
line derived mammospheres were not affected by tamoxifen, in fact, tamoxifen increased the 
mammosphere formation at higher concentrations from MCF7 and ZR-75-1 cells. Further, 
treatment with tamoxifen significantly increased the expression of stem cell genes such as 
Oct4, Sox2, Nanog and Notch1 on MCF7 spheres compared to vehicle controls, indicating its 
potential stem cell enhancing phenotypic effect. 
In order to investigate the biological process involved in the tamoxifen resistant phenotype of 
CSCs, we performed whole transcriptome analysis on tamoxifen treated mammospheres 
derived from seven patients. Gene set enrichment analysis revealed “ribosome synthesis” and 
“mRNA translation” processes up regulated by tamoxifen. Further, we observed that these 
processes were induced only in tamoxifen treated CSC population but not in tamoxifen treated 
adherent MCF7 cells using publically available datasets.  mTOR is the central regulator of 
ribosome synthesis and mRNA translation process, therefore we hypothesized that tamoxifen 
could activate mTOR pathway and thereby rendering CSCs tamoxifen resistant. Key mTOR 
downstream effectors such as phosphorylated S6K1 (Thr389), S6RP (Ser235/236), 4E-BP1 
(Thr37/46) and mTOR (Ser2448) were investigated in tamoxifen treated patient derived 
mammospheres using both immunofluorescences (n=4 patients) and western blot (n=2 
patients). Tamoxifen treatment induced phosphorylation of mTOR effectors in CSCs, 
indicating the activation of mTOR pathway. Further this induction was observed only in CSC 
population but not in the differentiated adherent cells derived from patients. Inter-individual 
patient differences were observed in tamoxifen’s effect to induce mTOR pathway, as we 
observed hyper activation of mTOR signalling already present in CSCs derived from some 
patients. We confirmed the activation of mTOR pathway in CSCs by comparing MCF7 
adherent cells and mammospheres generated from MCF7 cells.   
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We used two mTOR inhibitors (rapamycin and everolimus) and one dual mTOR/PI3K 
inhibitor (PF04691502) to check if these inhibitors can counteract the mTOR activation 
induced by tamoxifen on CSCs. In both patient (n=2) and cell line derived mammospheres 
(MCF7 and T47D), we were able to demonstrate that these compounds antagonized the effect 
of tamoxifen. Due to hyper activation of mTOR pathway in CSCs derived from cell lines, we 
used restrictive media (without insulin, EGF and FGF) to reduce the endogenous mTOR 
stimulation. Combination treatments (tamoxifen + mTOR inhibitors) revealed that tamoxifen 
induced downstream mTOR effectors when compared to mTOR inhibitors treatment alone on 
CSCs. Further, mammosphere formation assay on three patient and two cell line (MCF7 and 
T47D) derived CSCs demonstrated that all the investigated mTOR inhibitors reduced 
mammosphere formation significantly and the dual mTOR/PI3K inhibitor being the most 
effective one irrespective of tamoxifen treatment.  
Tamoxifen is the most prescribed drug for endocrine therapy as it has profound effects on cell 
proliferation of bulk tumor cells. However, the effect of tamoxifen on CSCs are not well 
established. There are reports suggesting that tamoxifen resistant MCF7 cells enrich CSCs 
formation364 and these studies have most often been based on ERα-positive MCF7 cells. 
Therefore, it is important to study the effect of tamoxifen on patient derived CSCs. In this 
study, using microarray analysis on tamoxifen treated CSCs revealed activation of “ribosome 
synthesis” and “mRNA translation” which are regulated by mTOR. We show that, tamoxifen 
has a non-expected side effect by inducing mTOR pathway in CSCs. We believe this effect 
can contribute to tumour recurrence and therapeutic resistance. Although, the exact mechanism 
of how tamoxifen induces mTOR pathway is not yet investigated, there are few possible 
mechanism we can speculate. Since CSCs are known to have lower ERα expression and the 
effect of tamoxifen stimulation was observed even on CSCs derived from ERα negative 
patients in our study, the effect could be meditated via ERβ or any other estrogen binding 
receptors such as GPER (G-protein coupled receptor 30). Few reports support this hypothesis 
as tamoxifen acts as agonist via GPER in various cancer cell lines365,366. More investigation is 
needed to fully understand this mechanism. 
In summary, we report an increased activity of mTOR pathway in CSCs and it is further 
induced by tamoxifen therapy. However, this induction could be antagonized by adding mTOR 
inhibitors. Combined treatment with tamoxifen and mTOR inhibitors can be a potential 
strategy to eradicate both bulk tumour and CSC population in parallel to avoid cancer 
recurrences.   
4.4 PAPER IV 
Genomic analyses of primary breast cancers and multiple matched metastatic lesions 
reveal both linear and parallel progression with minimal role of axillary lymph node 
metastasis 
Metastasis is  the main reasons for breast cancer mortality272. Currently, metastatic disease are 
not curable as it is treated based on the primary tumor characteristics. We and others have 
shown that prognostic and therapy predictive markers alter during breast cancer progression 
164,367 which significantly influences their survival. These alterations highlights that breast 
cancer progression is a dynamic process where an ongoing evolution of heterogeneous cancer 
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cell populations give rise to treatment resistant clones under therapeutic pressure84. Therefore, 
it is important to investigate the genomic landscape of metastatic breast cancer with respective 
to their corresponding primary tumors to identify novel therapeutic targets and biological 
processes involved in metastasis formation. Further little is known regarding the patterns of 
breast cancer spreading and the involvement of ipsilateral axillary lymph node metastasis in 
breast cancer progression. To address these issues, we have performed whole exome 
sequencing on 99 tumor samples from 20 breast cancer patients with multiple spatially and 
temporally distributed primary tumors, local recurrent, axillary lymph node and distant 
metastasis.   
We observed high inter-individual differences in the number of mutations shared between 
primary cancers and metastasis, indicating varying points of divergence from primary tumor to 
distant metastasis. On average 55% of primary mutations were retained in the distant metastatic 
lesions with considerable disparity between individual patients ranging from 9 to 88%. In order 
to investigate the timing of putative driver events during cancer progression, we used a set of 
putative driver genes in breast cancer compiled by Yates et al 83. Driver alterations such as 
TP53, PIK3CA, PTEN and GATA3 mutations, and MYC and ERBB2 amplifications were 
predominantly early events, however, a few were late events occurring privately in distant or 
lymph node metastasis. These included NOTCH2 and MED12 mutations, as well as AKT2 and 
EGFR amplifications. These data suggests that distant metastatic lesions exhibit high inter-
individual differences in genomic disparity when compared to its respective primary tumors 
and late driver event alterations are common during cancer progression.  
In order to determine the patterns of metastatic spread, we used Dollo Parsimony368 to 
investigate the evolutionary history of cancer cells across different sites from the same 
individual. We used the separating property in phylogenetic trees to infer the progression 
patterns in metastatic breast cancer. In addition to this, we used a Bayesian clustering method 
called PyClone369 to infer the subclonal composition of the same set of data. To determine the 
progression pattern, we need sequencing data from primary cancer and more than one distant 
metastases from the same patient. Five patients (patients 1, 4, 5, 8 and 19) were suitable for 
this analysis. Using the phylogenetic tree re-construction we inferred that four out of the five 
patients (patients 1, 5, 8 and 19) followed a linear progression model that is successive 
metastasis-to-metastasis spreading of tumor cells. Additionally, subclonal analysis revealed 
that, in all of the four patients, one or more subclones were shared specifically between 
different metastases, but not with their corresponding primary cancers. However, one patient 
(patient 4) followed parallel progression model 321, that is distant metastases seeded directly 
from primary tumor rather from other metastases. No subclones were shared exclusively either 
among all or between any pair of distant metastases in this patient. Subclonal analysis revealed 
both monoclonal and polyclonal seeding from primary breast cancer to distant metastases in 
our cohort. Four out of fifteen patients (patients 8, 15, 17 and 19) followed monoclonal seeding 
(27%) and eleven out of fifteen patients (patients 1, 2, 3,4,5,9,10,11,14, 18 and 20) followed 
polyclonal seeding (73%). Next, we analyzed eight patients (patients 2, 3, 8, 10, 14, 15, 17 and 
18) having primary cancer, ipsilateral axillary lymph node metastasis and distant metastasis 
using the separating property in phylogenetic trees. This analysis revealed very low support for 
ipsilateral axillary lymph node-based seeding to distant organ metastases. Subclonal analysis 
revealed that, except for one patient (patient 3), no subclones were shared exclusively between 
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axillary lymph node metastases and any distant metastases thus complementing the 
phylogenetic results. 
Apart from clonal evolution, we also investigated the activity of different mutational process 
involved in breast cancer progression. At least four signatures were found operative in our 
cohort and three of them were mapped to known mutational processes such as “age at 
diagnosis”, “APOBEC” and “deficient homologous recombination (HR)” 370. We evaluated 
signature contributions across site-specific categories in patients to assess their signature 
contribution separately. We observed increased activity of mutational processes of APOBEC 
signature (p-value < 0.01), unknown etiology signature (p-value < 0.05) and HR signature (p-
value < 0.05) in metastasis-specific relative to the primary-specific category. 
 One of the most important observations from our study is the lack of axillary lymph node 
metastasis involvement in seeding distant metastasis. Even though nodal status have an 
unquestionably high prognostic value 333,371, we demonstrate that they are not responsible for 
further seeding of cancer cells. Nodal status might reflect only the tumor biology of the breast 
cancer with acquired capability of cancer to survive, migrate and proliferate in other organs 
thereby having high prognostic value. Hence, dissection of positive axillary lymph nodes will 
not reverse this acquired capability since spreading to distant sites occurs in a different path 
and most likely directly from the primary tumor. Our data suggests that breast cancer spreading 
is a complex process, where we observe both linear and parallel progression with frequent 
polyclonal seeding and the existence of an ongoing evolution of mutational signatures during 
breast cancer progression. Together these observations relate to several factors challenging the 
prevention and treatment of metastatic breast cancer. 
4.5 PAPER V 
Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based 
molecular profiling 
In breast cancer, determining the tumor grade and molecular subtype by IHC surrogate 
classification is highly sensitive to the cut-off of Ki67 as well as the region of the tumor 
investigated372,373. Further, inter-individual variability between pathologists also accounts for 
variations in tumor classification374,375. Therefore, next generation technologies such as 
automatic pathology image processing, gene expression based molecular profiling and genetic 
testing are considered as the future of cancer diagnostics. In order to translate such technologies 
to the clinic, they should be sufficiently robust and consistent in providing therapy predictive 
and prognostic information without being affected by intra-tumor heterogeneity. 
Transcriptomic profiling of breast tumors provides opportunity for subtyping and molecular-
based patient stratification for prognostic and therapy prediction purposes. For reliable 
transcription based molecular profiling as well as for biobanking, it is essential that the region 
of the tumor profiled represents the whole tumor and is not influenced by intra-tumor 
heterogeneity.   However, breast cancers commonly exhibit intra-tumor heterogeneity at both 
a molecular and morphological level, which can arise during tumor evolution. Currently it is 
not established to what extent a random sampling approach may influence molecular breast 
cancer diagnostics.  
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In this study we applied RNA-sequencing to quantify gene expression in 43 pieces (2-5 pieces 
per tumor) from 12 breast tumors. We determined molecular subtype and transcriptomic grade 
for all tumor pieces and analyzed to what extent pieces originating from the same tumors are 
concordant or discordant with each other. Molecular subtyping was consistent in 11 out of 12 
12 tumors. Similarly, transcriptomic grade assignments were consistent in 11 out of 12 tumors 
as well. Additionally, we validated our finding in an independent retrospective cohort 
consisting of 19 pieces (2-6 pieces per tumor) from 6 breast tumors profiled using microarray 
technique. Molecular subtype predictions revealed consistent subtypes in four out of six 
patients in this cohort. Further, we also performed whole exome sequencing on these 19 tumor 
pieces (from 6 patients) to investigate intra-tumor genomic heterogeneity in breast cancer. 
Interestingly, we observed extensive intra-tumor genomic heterogeneity (based on putative 
driver gene variant allele frequencies and subclonal analysis) in these tumor pieces but not in 
their molecular subtype classifications. 
Our data suggest that the average expression profile collected from any part of the tumor in 
most cases is representative for the entire tumor, at least with respect to transcriptomic grade 
and molecular subtype with existing microarray technologies. Further, the variability 
introduced by random sampling of material from the tumor is not expected to have a major 
impact for most patients for transcription based molecular diagnostics, even though these intra-
tumor pieces demonstrates substantial intra-tumor genomic heterogeneity.  
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5 FUTURE PERSPECTIVES 
Future perspectives for all the studies included in this thesis are individually summarized 
below. In the first study, we have optimized the protocol for bio-banking small breast tumors 
for future research purposes, where we have demonstrated that, DNA and RNA isolated form 
the scraping material are in sufficient quality to perform next generation sequencing and 
microarray analysis. In future, apart from bio-banking tumor samples we aim to establish 
patient derived ex-vivo tumor cultures for therapy prediction and drug discovery purposes. We 
are currently optimizing protocols to establish whole tumor cultures (WTC) and organotypic 
cultures (fresh tissue sections) from patient derived tumor samples. Preliminary data from these 
ex-vivo cultures suggest that they retain key therapy predictive biomarkers such as 
ER/PR/HER2 and Ki67. One of the advantages with organotypic culturing is that it retains the 
tumor micro environment i.e., the cultured tumor sections retains fibroblasts, infiltrated 
immune cells and tumor cells. Using these ex-vivo cultures, the aim is to predict if a patient 
will respond to a particular therapy or not ex-vivo. The specific panel of biomarkers to verify 
therapy response is currently investigated.   
Results from paper II reveals that BSCs express ERβ, which can be used as a potential 
therapeutic interventions against BSCs and can be used in combination with present 
chemotherapeutics and endocrine therapies for targeting both differentiated cancer cells and 
BSCs in parallel. Further, in this study we identified the potential mechanism by which ERβ is 
maintaining breast cancer stem cell phenotype. Stimulation of ERβ in BSCs aid the shift 
towards glycolytic metabolism which in turn maintains cancer stem cell phenotype. Further, 
breast cancer stem cells were found to be relying on fermentative glycolysis and are sensitive 
to glycolytic inhibitors360. These studies highlight the importance of glycolytic metabolism for 
BSC survival. Glycolytic inhibitors are reported to be efficient in targeting cancer cells with 
mitochondrial defects or under hypoxic environment, which are often associated with 
conventional therapy resistant phenotype, similar to CSCs74. There are many ongoing pre-
clinical/phase I-III clinical trials with glycolytic inhibitors as anti-cancer therapeutics376. 
Therefore, it is highly interesting to investigate the combination of glycolytic inhibitors and 
traditional chemo/ endocrine therapies against cancer as it targets both CSC and more 
differentiated cancer cells using patient derived CSCs, xenograft (PDX) and ex-vivo models.   
In our next study, we demonstrated that tamoxifen treatment of BSCs induce mTOR signaling 
pathway, thereby conferring endocrine resistance. However, the upstream biding partners and 
key regulators involved in tamoxifen induced mTOR activation in BSCs are yet to be identified. 
Since, BSCs are ERα negative, it is tempting to speculate the second estrogen receptor ERβ 
could potentially mediate the mTOR activation during tamoxifen treatment in BSCs. More 
mechanistic studies are required to address this hypothesis. Apart from ERα and ERβ, there is 
another novel estrogen receptor named G-protein coupled receptor 30, which is also referred 
as GPER, structurally different from the classical ERs377. Interestingly, anti-estrogen therapies 
such as tamoxifen and fulvestrant acts as a GPER agonist and induce cell proliferation in 
endometrial and thyroid carcinomas366,378,379. Cell viability and motility was induced in triple 
negative breast cancers when treated with 17β-estradiol (E2) and tamoxifen via GPER380. 
These data suggests that, GPER might be another potential mediator of tamoxifen induced 
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mTOR activation in BSCs. Therefore, GPER expression and its role in BSCs can be a potential 
future project to expand our knowledge on estrogen signaling in BSCs.   
In our next study, we focused on the genomic relationship of matched primary tumors and 
distant metastatic lesions from twenty breast cancer patients. This study demonstrated the 
complex patterns of metastatic spreading with lack of axillary lymph node metastasis 
involvement in seeding distant organ metastasis. This conclusion could have important clinical 
implication and must be confirmed in a larger cohort. Apart from exome sequencing, we have 
also performed microarray analysis on all the tumor samples (including both primary and 
distant metastases). Using this gene expression profile we have reported PAM50 molecular 
subtype switching in four patients in total out of fifteen patients for which we have PAM50 
subtype information. In future, we are planning to perform gene set enrichment analysis 
(GSEA) by grouping all primary tumors versus distant metastases to identify biological process 
which are enriched and down-regulated in metastases. Further, it is still unclear whether 
mesenchymal epithelial transition (MET) process in crucial for metastatic cells at distant sites 
to gain growth advantage in breast cancer patients. Therefore, we aimed to investigate the 
epithelial mesenchymal transition (EMT) process regulation in actual distant metastases with 
respective to its primary tumors using both gene expression data and immunohistochemical 
(IHC) staining of EMT biomarkers. In our final study, we have reported that spatial intratumor 
heterogeneity has limited impact on transcriptomic analysis in breast cancer. In the future, we 
would like to increase the cohort size with more representation of different molecular subtypes, 
to validate if intrinsic molecular subtypes can influence the extent of intra tumor heterogeneity 
which in turn can affect current transcription based diagnostic technologies.  
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